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A B S T R A C T 
Previous studies demonstrated that in the testis, VEGF was principally 
expressed in Leydig cells though lower levels of expression were also found in Sertoli 
cells and vascular smooth muscle. The overall aim of the present investigation was to 
examine the control ofVEGF expression in the testes using the technique ofNorthem 
blot analysis, and based on studies performed in rats and on in vitro cultures of mouse 
testicular cell lines - TM3 Leydig cells and TM4 Sertoli cells. 
- Hypoxia (1% O2, 5% CO2, 94% N2) induced an upregulation of VEGF 
expression in TM3 and TM4 cells, and the effect could be mimicked by cobalt 
chloride (C0Cl2) treatment. VEGF mRNA levels increased after 1-3 hours, peaked at 
6-12 hours and then returned to lower values after 24 hours. In TM3 cells, the C0Cl2 
effect was concentration-dependent and the maximum induction of VEGF occurred 
with a dose of300-600 pM. The hypoxic induction ofVEGF expression appeared to 
be relevant to the in vivo situation of testicular ischaemia caused by spermatic cord 
torsion since the surgical induction of this condition in adult rats resulted a 1.3-fold 
increase in the testicular levels ofVEGF mRNA. 
In TM3 cells, nitric oxide Q^0) antagonized the hypoxia-induced increase in 
VEGF expression. The presence ofNO donors - 100 i^M SNP or 500 _ SNAP, 
reduced the increase in VEGF mRNA levels caused by hypoxia, without affecting the 
basal expression under the normoxic state, while lmM L-NAME (a NO synthase 
inhibitor) had no effect on either. These data suggest that NO is a negative regulator 
of VEGF expression in Leydig cells even though in TM3 cells their endogenous NO 
production is probably low or absent. 
i 
Cadmium induced a time- and concentration-dependent increase in VEGF 
expression in TM3 and TM4 cells, with the maximum changes occurring at 6 hours 
with 30 [jM CdCl2. In TM3 cells, the effect of cadmium was antagonized in the 
presence of dexamethasone (1 i^M). These in vitro data agreed well with the in vivo 
findings ofan induction ofVEGF mRNA expression in the testes of adult rats injected 
6 or 12 hours previously with CdCl2 (6 mg/kg), and the abolition of the increase (and 
the associated vascular permeability changes) by prior dexamethasone treatment. The 
fact that VEGF expression in both Leydig cells and Sertoli cells could be upregulated 
• by Cd treatment also explained why removal ofLeydig cells in the rat testes reduced 
but did not abolished the increase in VEGF mRNA levels in response to Cd. 
hCG (1 KJ/ml) could within 2 hours induce a 3-fold increase in VEGF mRNA 
levels in MLTC-1 cells that are known to retain their LH responsiveness，and the 
stimulatory effect was shown to be both time- and concentration-dependent. On the 
contrary, neither TM3 nor TM4 cells could respond to their respective trophic 
hormone with an upregulation ofVEGF expression. Nevertheless, the cAMP/protein 
kinase A pathway appeared intact in TM3 and TM4 cells, and would be involved in 
the regulation of VEGF expression as indicated by the time- and concentration-
dependent stimulatory effect of forskolin [or 8-(4-chlorophenylthio)-cAMP] on 
VEGF mRNA levels in these cells. On an equimolar basis (1 i^M), phorbol-12-
myristate-13 -acetate ^^MA) had a more potent and sustained action than forskolin in 
stimulating a rise in VEGF mRNA levels in both TM3 and TM4 cells. This would 
indicate that the protein kinase C pathway might play a more important role in the 
control ofVEGF expression in the testis. 
ii 
When macrophage-derived cytokines (10 ng/ml) were examined for their 
effects on VEGF expression in TM3 Leydig cells, only TNF-a and TNF-p (but not 
n , - la , EL-ip and JL-6) were shown to have weak stimulatory action after 12 hours of 
treatment, and this was shown to be dose-related. Both bFGF and TGF_pi produced 
a significant stimulation of VEGF mRNA levels in TM3 cells at 24 hours after 




endothelial growth factor，VEGF)主要表達於萊迪希氏細胞(Leydig 
cells)，亦有少量見於画托立氏細胞(Sertoli cells)和血管平滑肌 
(vascular smooth muscle ) °本實驗利用活大白鼠和兩種體外(m 
vitro )培養的小白鼠睪九細胞株(cell Knes ) � 1乂 3萊迪希氏細胞 
株和 1乂 4謝爾托立氏細胞株，藉著北方印跡術（ N o r t h e n 
blotting)，去考察睪九血管內皮生長素基因表達(gene expression) 
- 的調節機制。 










^^^八表達的作用。兩種一氧化氮供體（N0 donors) — 100微摩爾 







在TM3和TM4細胞株中，氯化鎘（CdCk )能增進 V E G F 
的表達，並呈現時間和濃度依賴性，在6小時和30微摩爾濃度達到 
高 峰 。 此 外 ， 在 T M 3 細 胞 株 中 ， 1 微 摩 爾 的 地 塞 米 松 
(dexamethasone)能克制氯化鎘的效應。在大白鼠體內注射氯化鎘 


















因子06 (TNF-a)和腫瘤壞死因子0 (TNF-p)在12小時後只能微增 
VEGFmRNA水平，並呈現濃度依賴性；相反，白細胞介素-la 
(工-la)，白細胞介素-ip (IL-ip)和白細胞介素-6 (工-6)則沒 
有反應°此外，鹹性成纖維細胞生長因子（bFGF)和轉化生長因 
子-pl ( TGF-pl )能在24小時後，有效地增加VEGF m R N A的水 
平，並且在10-30 ng/ml的濃度時達到最高效應。 
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1. /ntroduction 
1.1 General review of the testis 
1.1.1 Structure and function of the testis 
The testes are oval, paired structures suspended by the spermatic cords and 
housed within the scrotum. Each testis is surrounded by a membranous capsule whidr 
is made up of three distinct layers, namely tunica vasculosa, tunica albuginea and 
tunica vaginalis. The testis parenchyma is structurally and functionally divided into 
. two compartments - the seminiferous tubules and the intertubular tissue (or 
interstitium). Lining the seminiferous tubules is a compound epithelium consisting of 
germ cells and Sertoli cells. Production of spermatozoa occurs within these tubules in 
a process known as spermatogenesis. The interstitium contains lymphatic vessels, 
blood vessels, variable amount of connective tissues and a variety cell types including 
Leydig cells, macrophages, fibroblasts and mast cells. 
The testes subserve two major functions in adults, namely the production of 
spermatozoa and the secretion of androgens，mainly testosterone. These functions are 
known to be regulated primarily by the two gonadotrophins produced by the anterior 
pituitary - follicle stimulating hormone (FSH) and luteinizing hormone (LH). The 
release ofthese two hormones is in tum under the control of gonadotrophin releasing 
hormone (GnRH) produced by the hypothalamus. FSH acts specifically on the Sertoli 
cells to support the process of spermatogenesis. LH acts on the Leydig cells to 
stimulate androgen production which is needed for the development and maintenance 
of the spermatogenic process as well as the secondary sexual characteristics. In 
addition to the hypothalamic-pituitary control of testicular functions, there is 
increasing evidence to indicate that hormone actions within the testis are modulated 
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by numerous paracrine and autocrine factors [reviewed in Huhtaniemi & Toppari， 
1995; Jegou & Pinau, 1995] produced locally as a means of cell-cell interactions. 
1.1.2 Testicular vasculature 
In mammalian testes, the vascular system possesses several peculiar structural 
-organisations which indicate that it has important control over the function of the 
testis [see reviews by Bergh et al., 1993; Setchell et aL, 1994]. These include a long 
unbranched testicular artery, the presence of a peritubular and an intertubular capillary 
network, the lining ofthe testicular vasculature by an unfenestrated endothelium and 
the failure of the capillaries to penetrate the seminiferous tubules. Due to the 
haemodynamic properties ofalong unbranched blood vessel, the rate ofblood flow to 
the testis is intrinsically limited by the testicular artery. An unfenestrated endothelium 
may impede the passage of important macromolecules like the gonadotrophins, from 
blood to their target cells in the extravascular tissues. In addition, the above problems 
could be compounded by the fact that the seminiferous tubules which make up the 
bulk ofthe testicular tissues and possess the actively dividing and differentiating germ 
cells, are avascular. Since oxygen has to diffuse from the capillaries lying in the 
intertubular areas to the seminiferous tubules, the centre of these tubules has been 
shown to be at the brink ofhypoxia [Setchell, 1978]. This is especially true when the 
metabolism within the testis is increased (e.g. elevated testicular temperature) without 
being matched by a corresponding rise in blood flow. In the view of the limitations 
imposed by the anatomical arrangement of the testicular vasculature, a well-developed 
and maintained blood supply appears to be extremely important to the normal 
activities within the testis and may provide the necessary local control of testicular 
function. In the vascular control within the testis, besides the acute effects from the 
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alteration of the vascular permeability, and the regulation of blood flow by 
vasodilation or vasoconstriction, there is a medium- to long-term regulation by 
controlling the blood vessel formation or angiogenesis. 
1.1.3 Testicular angiogenesis 
It remains to be elucidated how the angiogenic process in the testis is initiated -
and controlled. However, many angiogenic factors have been found in mammalian 
testes [Ergun et al, 1997; Gnessi et aL, 1997; Norrby, 1997]. According to the 
distinction proposed by Folkman and Haudenschild [1980], there are two categories 
of angiogenic factors. Direct factors are those that could elicit angiogenesis, 
endothelial cell migration/proliferation both in vitro and in vivo, and the indirect 
factors are the ones that cannot induce angiogenesis on their own in vitro but can do 
so only in vivo by inducing other cells to secrete direct angiogenic factors. 
Among the direct angiogenic factors，acidic fibroblast growth factor (aFGF), 
basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) and 
vascular endothelial growth factor (VEGF) are found in the testis [Zheng et al, 1990; 
Murono et al, 1992; Gnessi et al, 1995; Ergun et al, 1997]. However, only VEGF 
has the signal peptide required for secretion and also it is mitogenic only to 
endothelial cells pLeung et al, 1989; Ferrara, 1996; Ferrara & Davis-Smyth, 1997]. 
So it makes VEGF a very attractive candidate for the study of how the angiogenic 
process is being regulated within the testis. 
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1.2 Vascular Endothelial Growth Factor (VEGF) 
1.2.1 Discovery ofVEGF 
Vascular endothelial growth factor (VEGF) was first discovered and 
characterized based on its ability to induce endothelial cell-specific mitogenesis in 
vitro [Connolly et aL’ 1989a; Keck et al., 1989; Leung et aL, 1989a; Levy et al, 
1989a; Plouet ~et al, 1989; Tischer et al,’ 1989; Conn et aL, 1990a，1990b]. By 
amino acid analysis and DNA sequencing, this protein was found to be identical to the 
vascular permeability factor (VPF) which was secreted by rodent tumour cell lines 
[Senger et aI., 1983; Keck et aL, 1989]. VEGF displays limited by significant amino 
acid sequence homology to the A and B chains of PDGF (18-20%), and to the 
placental growth factor (PlGF) (53%) [Maglione et al, 1991; Thomas et al, 1996] 
with which it can form heterodimers. 
1.2.2 Organization of VEGF gene 
The human VEGF gene is composed of eight polypeptide coding exons 
separated by seven introns, and its coding region spans approximately 14 kb 
(kilobase) [Houck et al, 1991; Tisher et aL, 1991]. It has been assigned to human 
chromosome 6p21.3 [Vincenti et al, 1996]. Complementary DNA (cDNA) sequence 
analysis of a variety of human VEGF clones has indicated that VEGF may exist in 
four different isoforms having 121，165, 189 and 206 amino acid residues (VEGFm， 
VEGFi65, VEGFi89, VEGF206). It has now been well established that alternative exon 
splicing of a single VEGF gene is the basis for this molecular heterogeneity [Houck et 
al.’ 1991; Tischer et al, 1991;Ferrara et al, 1992; Charnock-Jones et al, 1993]. 
The shortest form of the VEGF protein is encoded by exons 1-5 and 8 
[Tischer et al, 1991], while VEGFi6s lacks the amino acid residues encoded by exon 
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6. Compared with VEGFi6s, VEGF121 lacks 44 amino acids. VEGFi89 has an 
insertion of 24 amino acids highly enriched in basic residues, and VEGF206 has an 
additional insertion of 17 amino acids. Interestingly, there is no intron between the 
coding sequence of the 24-amino acid insertion in VEGFi89 and the additional 17-
amino acid insertion found in VEGF206. 
The organization of the murine VEGF gene has also been described [Shima et 
aL’ 1996]. Similar to the human gene, the coding region of the murine VEGF gene 
encompasses approximately 14 kb and is comprised of eight exons interrupted by 
seven introns. All four isoforms in rodents are shorter than the corresponding 
isoforms in human by one amino acid [Shima et al., 1996]. 
Based on cDNA analysis, the N-terminal ofVEGF was shown to be preceded 
by a sequence of 26 hydrophobic amino acids that corresponds to a typical signal 
peptide. This leader sequence offers the potential for VEGF to be secreted from cells 
[Leung et aL, 1989; Neufeld et al, 1994; Thomas et aL, 1996], which the other 
commonly known angiogenic factors or endothelial cell mitogens, such as fibroblast 
growth factor (FGF) and platelet-derived growth factor ^PDGF), do not possess. 
1.2.3 Properties of the VEGF isoforms 
Native VEGF is a family of disulphide-linked heparin-binding homodimeric 
glycoproteins P^errara et aL, 1992; Dvorak et al.’ 1995; Ferrara, 1996; Ferrara & 
Davis-Smyth, 1997]. Its molecular weight ranges from 34-56 kDa (kiloDalton) 
pFerrara et aL, 1992]. Analyses of a variety of tissues and cultured cells have shown 
that VEGFi65 is the most abundant isoform in most tissues under physiological 
conditions [Ferrara et aL, 1992]. Transcripts encoding VEGF121 and VEGFi89 are 
also detected in the majority of cells and tissues expressing the VEGF gene [Houck et 
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al., 1991; Tisher et aL, 1991] while those of VEGF206 are less commonly found 
[Houck et aL, 1991; Cheung et al, 1998; Grutzkau et al, 1998]. 
Although there is no difference in the endothelial cell mitogenic activity among 
different VEGF isoforms, they have different heparin-binding activities depending on 
the polycationic seqeunce near the C-terminal ends [Thomas, 1996]. The shortest 
form of VEGF - VEGFni, is-a secreted peptide and it does not bind to heparin 
[Houck et aL, 1992]. VEGFi65, is a heparin-binding growth factor [Park et al, 1993; 
Neufeld et al., 1994] and it is also a secreted protein [Houck et al, 1992; Peretz et 
al., 1992] even though a significant fraction ofit may remain bound to the cell surface 
and the extracellular matrix. In contrast，the longer forms - VEGFi89 and VEGF206, 
are more basic and they are not secreted. They are almost completely sequestered in 
the extracellular matrix [Park et al, 1993] and/or bound to cell surface heparin-like 
molecules on producing cells with greater affinity than VEGFies [Houck et al.’ 1991; 
Houck et aL, 1992]. Alternative splicing ofVEGF mRNA therefore also provides the 
means by which the physiological actions ofVEGF can be modulated. It can alter the 
proportion of VEGF peptides that can diffuse from their cellular sites of synthesis, 
bind to and store locally inside cells or attached to heparan proteoglycans in the 
extracellular matrix [Thomas, 1996]. 
1.2.4 VEGF Receptors 
The actions of VEGF have been found to be mainly mediated through two 
forms of high-affinity, membrane-bound receptors. Both receptors belong to the 
receptor tyrosine kinase (RTK) family and constitute a subgroup within the class III 
tyrosine kinases [Shibuya et al, 1990; Terman et al, 1991， 1992; De Vries et al.， 
1992; Jakeman et al” 1992; Simorre-Pinatel et al, 1994; Waltenberger et al, 1994; 
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Thieme et aL, 1995]. Each receptor is about 1,300 amino acid residues long. It is 
composed of an extracellular domain of 7 immunoglobulin-like repeats and a ligand-
binding region, a transmembrane domain, and a cytoplasmic domain containing a 
tyrosine kinase insert [De Vries et al, 1992; Terman et aL, 1992; Thomas et aL, 
1996]. Like other growth factor transmembrane tyrosine kinase receptors, VEGF 
receptors are believed to undergo ligand-induced dimerization to trigger intracellular 
signal transduction [Thomas, 1996]. 
VEGF receptor 1 (VEGFR1) or fins-like tyrosine kinase-1 (flt-l) was initially 
cloned from a human placenta cDNA library [Shibuya et al., 1990]. VEGF receptor 2 
(VEGFR2) or fetal liver kinase-1 (flk-l) was cloned from a fetal liver stem cell cDNA 
library in the mouse [Mattews et al, 1991; De Vries et al.，1992; Quinn et al, 1993]. 
For flk-l, the homologue that occurs in human is named kinase insert domain-
containing receptor ^CDR) which was cloned from a human umbilical vein endothelial 
cell cDNA library [Terman et al, 1991]. In the rat, the homologue of flk-1 is named 
tyrosine kinase C (TKrC) [Yamane et al, 1994]. Structurally, the amino acid 
sequences offlt-1 and KDR are about 45% identical [Terman & Dougher-Vermazen， 
1996]. 
Transfection studies of human flt-l and KDR revealed a stronger binding 
affinity between VEGF and flt-l than KDR [Jabbour et al” 1997]. Flt-l binds VEGF 
with 50-fold higher affinity than KDR [De Vries et al, 1992], however, KDR 
dominates the angiogenic response [Waltenberger et al, 1994] and is therefore of 
greater therapeutic interest. 
Many studies have demonstrated that both flt-l and flk-1 are exclusively 
expressed in vascular endothelial cells [Jakeman et al” 1992; Yamaguchim et al, 
1993; Barleon et al, 1994; Chakraborty et al., 1995]. They mediate the direct actions 
7 
of VEGF in stimulating endothelial cell proliferation and vascular permeability 
increase [Waltenberger et al., 1994]. They show overlapping but sometimes slightly 
different expression pattems. However, there is increasing evidence to indicate that 
.they are responsible for mediating different effects of VEGF. In the study of porcine 
endothelial cells, the effect of VEGF in causing cell proliferation and chemotactic 
migration appears to be mediated through binding to fIk-1 but not flt-l. The latter 
appears to play a more important role in endothelial organization during development 
PMustonen & Alitalo, 1995;Jabbour etaL, 1997]. 
Besides its action on vascular endothelium, VEGF has also been shown to be 
chemotactic to monocytes/macrophages. The receptor type found on these cells 
appears to be restricted to flt-1 though there has been a report of flk-1 
immunoreactivity found in human peritoneal macrophages [McLaren et al., 1996]. 
The presence of flt-1 in monocytes/macrophages is responsible for mediating the 
VEGF action in causing monocyte migration and activation [Clauss et al, 1990， 
1996; Shen etal, 1993;Bemhard etal, 1996]. 
The presence of multiple forms of VEGF and its receptors has the potential to 
greatly diversify the VEGF-induced signals in the target cells and may allow fine-
tuning of its actions. It has been hypothesized that the permeability and mitogenic 
activities of VEGF are mediated through different receptors since the concentration 
response curves for the two activities differ by at least two orders of magnitude [Shen 
et al., 1993;Wang et al, 1994]. 
1.2.5 Functions of VEGF 
The widespread constitutive expression of VEGF strongly indicates that it has 
numerous biological functions. It has been identified as an inducer of endothelial cell 
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growth and differentiation during development and neovascularization in a variety of 
physiological and pathological processes including embryogenesis preier et al., 
1992], corpus luteum formation [Ravindranath et aL, 1992], tumour growth pMate et 
al.，1992; Berkman et al, 1993; Aiello et al., 1994; Koch etal., 1994], inflammation, 
wound healing [Brown et al, 1992], diabetic retinopathy, rheumatoid arthritis, and 
compensatory angiogenesis in the heart [Banai et al, 1994b]. Endothelial cells 
throughout the vascular system can respond mitogenically to VEGF. Even if other 
less commonly studied cells were eventually shown to respond to VEGF, it remained 
to be the most selective vascular endothelial cell mitogen known. 
VEGF can also increase blood vessel permeability in vivo and in vitro [Senger 
et al, 1983; Banai et al, 1994a; Wang et al” 1994]. It has been shown that VEGF is 
5,000 to 50,000 times [Connolly et aI., 1989a; Keck et al” 1989; Connolly, 1991; 
Wang et al, 1994] more potent than histamine in the standard permeability bioassay. 
With the use of the Miles Test [Miles & Miles，1952], an intradermal injection or 
topical application of VEGF produces an increase in vascular permeability of 
postcapillary venules, muscular venules and capillaries within minutes pRoberts & 
Palade, 1995]. Some studies have suggested that VEGF causes vascular permeability 
increase by inducing fenestration in the endothelium [Breier et al, 1992; Brown et aI., 
1992; Roberts & Palade，1995]. 
An additional effect ofVEGF on the vascular endothelium is the stimulation of 
hexose transport pPekala et al, 1990]. Exposure ofbovine aortic endothelial cells to 
VEGF resulted in a significant increase in the rate of hexose transport. The 
combination of another factor TNF-a, resulted in an additive effect. This action may 
have relevance to satisfy energy demands of endothelial cells during proliferation 
under the inflammatory conditions. 
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VEGF has been reported to elicit non-mitogenic responses on monocytes, 
including chemotaxis and tissue factor production. Recruitment of mononuclear 
phagocytes from the blood compartment into tissue is a crucial process in 
inflammatory reaction and immune response. Clauss et al. [1990， 1996] and others 
Bemhard et aL, 1996] reported that VEGF isolated from tumour cell supematants 
induced monocyte migration and activation. These cells responded to VEGF with an 
increase in tissue factor production [Clauss et al.，1996] and intracellular calcium 
levels [Shen et al.’ 1993]. In human monocytes, the transient increase in cytosolic 
Ca2+ peaks at 30 seconds following the exposure to VEGFi65 [Shen et al, 1993；. 
1.3 VEGF in the testis 
1.3.1 Localization ofVEGF and VEGF receptors in the testis 
The first report indicating the presence of VEGF in the testis was the work 
done in the mouse where VEGF transcripts were localized by in situ hybridization in 
the testicular interstitium, most likely associated with the Leydig cells [Shweiki et al, 
1993]. Wan et al [1996] were the first to report on the cloning ofVEGF gene in the 
Leydig cells. Using immunohistochemical staining, Au et al. [1997] and others 
[Collin & Bergh， 1996] demonstrated that VEGF immunoreactivity was 
predominantly associated with the Leydig cells, though lower levels of expression 
were also found in the Sertoli cells and vascular smooth muscles. In line with the 
above findings, Ergun et al [1997] used RT-PCR and demonstrated that in human 
testes VEGF mRNAwas detected in Leydig cells and Sertoli cells. 
Using immunohistochemical staining, Au and his co-workers [Laslett et al, 
1997] were the first to demonstrate the presence of flt-1 immunoreactivity in a 
population of testicular interstitial cells that took up the trypan blue dye, suggesting 
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that they are testicular macrophages. In contrast, flk-l immunoreactivity appeared to 
be associated exclusively with the Leydig cells. More recently both flt-l and flk-l 
have been partially cloned from rat testicular macrophages and Leydig cells 
respectively [Au et al., 1998]. Flt-l is likely to be involved in the interaction between 
Leydig cells and macrophages as indicated by the ability of VEGF to induce testicular 
macrophage migration in vitro [Au et al, 1998]. In human testes, flt-4 mRNA was 
found by the technique of RT-PCR, to be expressed in human testicular tissue, 
isolated fragments of testicular blood vessels and seminiferous tubules. In addition， 
KDR mRNA was also found in total testicular tissue, isolated seminiferous tubules 
and testicular microvessels [Ergun et al, 1997]. 
1.3.2 Postulated functions of VEGF in the testis 
Since VEGF and its receptors are constitutively expressed in the testis, the 
following hypotheses have been proposed regarding their possible functions and 
regulation within the testis (detailed in Figure 1.1). 
1.4 Regulation ofVEGF 
1.4.1 VEGF, hypoxia and the testis 
Cells in tissues are faced with low oxygen tension under certain physiological 
(e.g. embryogenesis) as well as pathological (tumour growth, wound healing) 
conditions. Increasing evidence suggests that the survival of all higher forms of 
animal life depends on their ability to sense their oxygen environment and to adapt to 
it by improving oxygen delivery. These may involve the activation of hypoxia-
regulated genes, such as erythropoietin (Epo) [Beru et al., 1986; Bondurant & Koury， 
1986], VEGF [Plate etal, 1992; Shweiki et al, 1992], and platelet-derived growth 
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Figure 1.1 VEGF in the testis - its postulated functions and regulation. VEGF is 
secreted from Leydig cells (and Sertoli cells) to control testicular angiogenesis 
and vascular permeability increase. These processes may in tum be regulated by 
hormones such as LH which has trophic effect on Leydig cells and hence may be 
involved in the regulation of VEGF synthesis and release. In addition, VEGF 
released from Leydig cell (and Sertoli cell) may provide a chemotactic signal to induc  monocyte recruitment from the circulation or ma rophages migration. This would be in line with the presenc of VEGF receptor - Flt-1, on testicularmacrophages. I tum, testicula  acrophages may release cytokines or rowthfactors to gulat  he L yd g cell (and S rtoli cell) pr uction ofVEGF. 
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factor-B chain [Kourembanas et aL, 1990]. Their increased expression would 
represent an important adaptive mechanism to promote the transport of oxygen and 
new blood vessel formation under chronic hypoxic and/or ischemic conditions. 
The upregulation of the VEGF gene by hypoxia and ischaemia has been well 
demonstrated in a variety of normal and transformed cell types in vitro [Shweiki et 
a/., 1992; L^doux& FreHn，1993; Brogi et al, 1994; Goldberg & Schneider，1994; 
Hashimoto et al, 1994; Minchenko et aL, 1994; Ikeda et al, 1995; Nomura et al, 
1995; Tuder et al, 1995; Shima etal, 1995; Sandner et al, 1997b]. The mechanism 
by which hypoxia increases VEGF gene expression is however partially understood. 
It has been demonstrated that similarities may exist between the hypoxic induction of 
VEGF and Epo gene expression [Goldberg & Schneider，1994]. Hypoxia inducibility 
is conferred on both genes by homologous sequences. By deletion and mutation 
analyses, a 28-base sequence has been identified in the 5'- promoter region of the rat 
and human VEGF gene, and in transient expression assays, it has been shown to 
mediate the hypoxia-induced increase in gene transcription [Levy et al.，1995; Liu et 
aL, 1995]. This sequence also shows a high degree of homology and similar protein-
binding characteristics as the hypoxia-inducible factor 1 OfflF-l) binding site within 
the Epo gene, which behaves like a classical transcriptional enhancer pVladan & 
Curtin, 1993]. HTF-1 has been purified and cloned as a mediator of transcriptional 
responses to hypoxia and is a heterodimeric basic helix-loop-helix protein [Wang et 
al., 1995; Wang & Semenza, 1995]. Forsythe et al [1996] provided more direct 
evidence and demonstrated that a 47-bp hypoxia response element upstream to the 
VEGF transcription initiation site mediated Hff-1 gene expression. 
The induction of VEGF gene expression by hypoxia can be mimicked by 
cobalt chloride (C0Cl2) treatment [Wenger et al, 1996; Palacio et aL, 1997; Sandner 
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et al., 1997a，1997b]. In the study ofthe cobalt-induced Epo gene expression, it has 
been proposed that it acts by replacing iron in the porphyrin ring of a putative heme-
containing protein oxygen sensor, thereby locking the heme group in the deoxy 
.conformation and decreasing its affinity for oxygen in a manner analogous to hypoxia 
[Goldberg & Schneider, 1994]. 
In the testis, ischaemia can occur as a result of spermatic cord torsion. It is a 一 
urologic emergency in human, and has been estimated to occur as high as 1 in 158 
males by the age of25 [Anderson & Williams, 1986]. It is well known that patients 
with spermatic cord torsion may face infertility problems even if detorsion is carried 
out due to the irreversible damage to the seminiferous tubules. However, it remains 
unclear whether in longer terms, VEGF could compensate for the reduction in blood 
flow by stimulating the development of new blood vessels. 
1.4.2 VEGF, nitric oxide and the testis 
Nitric oxide Q^0) is a small gaseous molecule with a well-described role as a 
messenger molecule in a wide range of biological processes such as regulation of 
normal vascular tone, inhibition of platelet aggregation, neuronal transmission, and 
cytostasis [Moncada et al, 1991; Bredt & Snyder，1994]. NO synthase O^OS), the 
enzyme responsible for the production ofNO from L-arginine, has been demonstrated 
in many tissues. Three NOS isoforms have been identified in mammalian species 
pS[athan, 1992], and they are neural NOS (nNOS), inducible NOS (iNOS), and 
endothelial NOS (eNOS). 
Recently a number of studies have demonstrated the involvement of locally 
produced nitric oxide in mediating the effects ofVEGF. NOS inhibitors block VEGF-
induced proliferation of human umbilical vein endothelial cells [Papapetropoulos et 
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al., 1997] and bovine endothelial cells isolated from coronary postcapillary venules 
pVlorbidelli et al., 1996]. Furthermore, NOS inhibitors inhibit the VEGF- but not 
bFGF-mediated tumour angiogenesis [Ziche et al” 1997]. These studies suggest that 
endogenous NO production is necessary for and lies downstream to the growth-
promoting effect ofVEGF on vascular endothelial cells. 
In addition； NO may afso play a role in mediating the VEGF-induced increase 
in microvascular permeability [Fischer et al, 1999; Mayhan, 1999; Tilton et al, 
1999]. Wu et al [1996] demonstrated that inhibition ofNOS with N^-monmethyl-L-
. arginine 0^-MvlMA) abolished VEGF-induced venular hyperpermeability in isolated 
coronary venules. 
The fact that in some systems, the effects of VEGF are mediated through NO 
would suggest that VEGF could stimulate NO production. Indeed VEGF was shown 
to induce the expression of eNOS and iNOS in human umbilial vein endothelial cells 
[Hood et aL, 1998] via KDR receptors [Kroll & Waltenberger, 1998] and it 
stimulated NO production from rabbit and human endothelial cells in a dose-
dependent manner [van der Zee et al, 1997]. In retum, NO would act as a negative 
feedback regulator to inhibit the induced but not the basal expression ofVEGF pLiu et 
al, 1998; Ghiso et al, 1999]. Tsurumi et al [1997] showed that NO donors inhibit 
PKC-induced upregulation of VEGF by interfering with the binding of transcription 
factor activator protein-1 (AP-1) to the promoter region ofVEGF gene. 
In the testis, the presence of NOS has been demonstrated by 
inununohistochemical and biochemical techniques [Bumett et aL, 1995], suggesting 
NO can be produced by several different cell types including endothelial cells, 
testicular autonomic nerves, macrophages, mast cells and Leydig cells [Bredt et al” 
1990; Welch etal.’ 1995]. Using immunohistochemistry method, eNOS was localized 
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to the cytoplasm of adult rat Sertoli and Leydig cells. iNOS was expressed in 
cultured rat macrophages, Leydig cells [Tatsumi et aL, 1997] and Sertoli cells 
[Stephan et aL, 1995]. nNOS was localized to the endothelium of rat testicular 
arteries and to Leydig cells [Lissbrant et aL, 1997]. Thus it remains to be determined 
how NO may interact with VEGF within the testis since they are formed in close 
proximity to each other or by the same cell types (i.e. Leydig cells, Sertoli cells). 
1.4.3 Cadmium-induced testicular toxicity 
- Cadmium-induced testicular toxicity is quite specific, and it is only observed in 
species with scrotal testes, like the mice, rats, rabbits, guinea pigs and golden 
hamsters [Parizek and Zahor, 1956; Meek, 1959; Kar and Das, 1960; Chiquoine, 
1964; Erickson and Pincus, 1964]. Among the various organs that are known to be 
affected by cadmium ppriberg et al” 1974], injury to the testes occurs at a minute 
dose which is neither toxic nor produces morphologic alteration in other organs 
pparizek and Zahor, 1956], including liver, kidney and female reproductive system 
(ovary and uterus). 
In addition, differences exist in the degree of toxicity produced by cadmium in 
different strains ofmice [Chiquoine and Suntzeff，1965; Gunn etcd., 1965; Godowicz 
and Pawlus, 1979] and rats of different ages [Wong and Klaassen, 1979; Laskey et 
al, 1986]. But in general, the response of animals to cadmium treatment depends on 
the dose as well as the duration ofexposure. 
After cadmium treatment, the following sequence of pathological changes 
occurs in the testis. There is an initial marked increase in vascular permeability PKar 
and Das, 1960; Mason et al, 1964; Chiquoine, 1964; Maekawa et aL, 1965; Waites 
and Setchell, 1966; Clegg and Carr, 1967; Hodgen et al, 1969] leading to interstitial 
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edema, which is later followed by hemorrhage, anoxia, necrosis, and finally testicular 
atropy Parizek and Zahor, 1956; Meek, 1959; Parizek, 1960; Cameron and Foster, 
1963] due to the degeneration of the seminiferous epithelium. 
Although a number of hypotheses have been proposed to explain the 
cadmium- induced pathological changes in the testis (or other organs such as liver, 
kidney and lung), no consensus fes yet been" reached regarding the cause of the 
increased vascular permeability which appears to be the primary event leading to the 
subsequent tissue changes. Bergh [1990] demonstrated that in rats that had the 
Leydig cells removed by ethane dimethane sulphonate (EDS) treatment，cadmium-
induced toxicity in the testis remained, suggesting that the vascular permeability 
changes are not critically dependent on Leydig cells. It is possible that cadmium may 
act directly on the vascular endothelium and/or produces the effect indirectly via 
products emanating from the seminiferous epithelium. 
In view of the fact that VEGF is a potent inducer of vascular permeability 
increase and its expression can be upregulated by transition metal like cobalt，nickel 
and manganese psfamiki et al” 1995; Palacio et al, 1997], it would be of interest to 
determine whether the marked increase in vascular permeability associated with 
cadmium toxicity in the testis (or maybe in other tissues or organs as well) could have 
resulted from an increased level of VEGF expression and hence its action on the 
testicular vasculature. 
1.4.4 VEGF, glucocorticoids and the testis 
VEGF is a candidate for oedema induction that occurs in the brain and other 
tissues. Clinically, synthetic glucocorticoid - dexamethasone, can reduce brain 
tumour-associated vascular permeability increase through poorly understood 
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mechanisms. It may act through one or both of the two possible glucocorticoid 
receptor-dependent mechanisms, namely a reduction in the response of the 
vasculature to tumour-derived permeability factors (including VEGF) and a fall in 
VEGF expression by tumour cells [Heiss et al” 1996; Nauck et cd.’ 1998]. A study 
performed by MacHein et al [1999] showed that in C6 and GS9L rat glioma cell lines 
cultured under normoxic condition, there was a 50-60% downregulation of VEGF 
mRNA by dexamethasone. However, the inhibitory effect of dexamethasone on 
VEGF gene expression was markedly reduced when the tumour cells were cultured 
• under hypoxic condition. These data suggest that the hypoxia-induced upregulation 
of VEGF could partially overcome the inhibitory effect of the dexamethasone 
[MacHein et al” 1999]. There are numerous other reports on a negative regulation of 
VEGF gene expression by glucocorticoid both in vivo [Bruce et al, 1987; Edelman et 
al., 1999] and in vitro [Criscuolo et al” 1988; Iijima et al, 1993; Hoper et al, 1997; 
Klekamp et al, 1997; Schlaeppi etal, 1997; Gloddek et al, 1999]. It would appear 
that glucocorticoids may form an integral part in the control of VEGF gene 
expression, especially under stimulated conditions. 
In the testis, the major cell types expressing VEGF appears to possess the 
glucocorticoid receptors. Using light and electron microscopic immunocytochemistry, 
Schultz et al [1993] reported the localization of glucocorticoid receptors in the nuclei 
of Leydig cells, macrophages, fibroblasts, smooth muscle cells, endothelial cells and 
primary spermatocytes in adult rat testes. Northern blot analysis further demonstrated 
the presence of glucocorticoid receptors in Sertoli cells and peritubular cells [Levy et 
al, 1989b]. The occurrence of glucocorticoid receptors in Leydig cells, Sertoli cells 
and vascular smooth muscle cells would suggest that VEGF expression may similarly 
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come under the regulation of glucocorticoids through intracellular receptor-mediated 
mechanism(s). 
1.4.5 Hormonal regulation ofVEGF expression 一 importance ofLH 
Evidence is accumulating to indicate that VEGF is involved in mediating 
hormonally-regulated angiogenesis. VEGF is expressed in many endocrine glands 
(e.g. testis, thyroid, pancreas, adrenal and pituitary) and hormone-responsive tissues 
like the uterus, fallopian tube, placenta and breast [Toi et al, 1995; Gordon et al, 
1996; Fujimoto et al, 1998; Winther et al, 1999]. 
In the ovary, the role of gonadotrophins in stimulating the expression of 
VEGF mRNA has been investigated using cultured luteinized granulosa cells obtained 
from human ovarian follicles around the time of ovulation when a marked increase in 
follicular angiogenesis occurs P^eulen et al, 1995]. hCG or LH was shown to 
stimulate VEGF gene expression in both a time- and a dose-dependent manner, and it 
is a lot more potent than FSH. Laitinen et al [1997] demonstrated that primary 
cultures of human granulosa-luteal (GL) cells exposed to recombinant human FSH 
(rhFSH) on days 5-7 ofculture gave significantly higher levels ofVEGF mRNA. In a 
time-course studies, hCG was also shown to induce a rapid increase in VEGF mRNA 
levels in GL cells, similar to what had been observed in the studies of granulosa cells 
from human pSTeulen et aL, 1995] and rats [Koos, 1995]. Gonadotrophin suppression 
by GnRH antagonist treatment significantly lowered the increase in VEGF mRNA 
levels in transplanted ovaries ofimmature rats [Dissen et al, 1994], and this could not 
be compensated by injecting these animals with PMSG (pregnant mare serum 
gonadotropin), suggesting the activity of LH might be more important. Finally, 
conditioned medium from gonadotrophin-treated human ovarian carcinoma cells was 
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shown to be mitogenic to bovine endothelial cells, and this activity could only be 
blocked by neutralizing antibodies against LH or VEGF [SchifFenbauer et al.’ 1997]. 
Using RT-PCR, both LH and FSH were shown to produce a dose-dependent 
stimulation of VEGF expression in these cultured human ovarian cancer spheroids. 
Based on the above findings of a predominant LH effect in stimulating VEGF 
expression in the ovary, it would be tempting to speculate that LH might have a 
similar action in the testis to upregulate VEGF expression in Leydig cells. 
LHAiCG is known to cause vascular changes in the testis. Following a single 
subcutaneous injection of 50-100 KJ hCG into adult rats, vascular permeability 
increases together with an accumulation of interstitial fluid and a rise in blood flow 
[Setchell & Sharpe, 1981]. Most of these changes were apparent 8 hours after the 
hCG injection, and they progressed with time during the next 12-16 hours [Setchell & 
Sharpe, 1981]. The same dose ofhCG (100 KJ) has recently been shown to stimulate 
endothelial cell proliferation in the testicular vasculature [Au et aL, 1996; Collin & 
Bergh, 1996], with the maximum changes occurring at 2 days post-injection. The 
angiogenic response [Au et al, 1996; Collin & Bergh^ 1996] and the permeability 
increase [Setchell & Rommerts，1985; Collin & Bergli，1996] are dependent on 
factors originating from the Leydig cells as the changes are completely abolished 
following the depletion of Leydig cells by ethane dimethane sulphonate treatment. 
This would be expected since Leydig cells represent the only cell type in the testis that 
binds LHy'hCG [Mendelson et al.’ 1975]. The Leydig cell product that could best 
fulfill such a role is VEGF as it can induce vascular hyperpermeability, endothelial cell 
“ proliferation, and an increase in blood flow possibly through the local production of 
nitric oxide[Lopez etal, 1997; Ni etal, 1997; Tilton et al, 1999]. 
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LHy1iCG acts on Leydig cells by binding to specific G-protein coupled 
receptors on the cell membrane [Tsai-Morris et al, 1985]. This leads to the 
activation ofthe membrane bound adenylate cyclase to increase intracellular levels of 
cyclic AMP which in turn phosphorylates intracellular proteins through the cAMP-
dependent protein kinase (i.e. protein kinase A or PKA) [Marsh, 1975; Cooke et al, 
1979，Sala et al, 1979，Hsueh et al, 1983]. Activation of this^ignal transduction 
cascade can be mimicked by the use of forskolin - an activator of adenylate cyclase, or 
cell-permeable analogs of cAMP (e.g. 8-bromo-cAMP). In view of the fact that 
upregulation of VEGF expression can occur via the cAMP/PKA pathway [Harada et 
al.，1994; Hoper et al, 1997; Pueyo et al, 1998], the likelihood of an LH/hCG effect 
on VEGF expression in Leydig cells is worth exploring. 
In addition to the cAMP/PKA pathway, protein kinase C OPKC) has also been 
shown to play an important role in inducing VEGF mRNA expression [Kikkawa et 
al, 1989; Ohno et al, 1991; Claffey et al, 1992]. VEGF gene expression is 
increased in response to phorbol 12-myristate 13-acetate (PMA), a direct activator of 
PKC [Tischer et al, 1991; Finkenzeller et aL, 1992]. PKC is present in Leydig cells 
P^ikula et al, 1987; Michel et al, 1993] and its activation has a multitude of effects 
on Leydig cell functions, including desensitization of LH action at LH receptor site 
[Cooke et al., 1992]. Therefore it remains to be determined whether the VEGF 
expression in Leydig cells can be regulated via different second messenger pathways. 
1.4.6 VEGF and Leydig cell - macrophage interaction 
Resident macrophages are a regular and prominent cellular component in the 
testicular interstitium. It has been estimated that they comprise up to 25% of the 
interstitial cell population in the testis of mammals including man, monkey, rat and 
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boar [Fawcett et al, 1973; Niemi et al, 1986，Kem et al 1995]. Based on 
morphologic studies, testicular macrophages are seen to be closely associated with 
Leydig cells, and between the two cell types, they form specialized cytoplasmic 
interdigitations [Bergh, 1985; Hutson, 1994] which may provide an important channel 
of communication between the two cell types. 
The first report of a functional interaction between testicular macrophages and 
Leydig cells came when testicular macrophage-conditioned media were shown to 
stimulate testosterone production in adult Leydig cells either in the absence and 
presence of exogenous LH [Yee & Hutson, 1985]. Later studies however showed 
that when macrophage-derived cytokines were either stimulated to be released in vivo 
or added in vitro to cultured Leydig cells, the predominant effect was inhibitory, even 
though stimulatory or no effects had also been reported [Sun & Risbridger，1994; 
Wang et al, 1991]. 
During the prepubertal development in rats, the invasion of the testicular 
interstitium by macrophages coincides with the development and differentiation of 
adult Leydig cells [Hutson, 1990], indicating that Leydig cells may play a role in the 
recruitment of testicular macrophages. In vitro, macrophage-derived cytokines (e.g. 
EL-1P and EL-la，TNF-a, TGF-a) can in tum stimulate the proliferation of immature 
(but not adult) Leydig cells fHales, 1992], thus providing evidence for a two-way 
interaction. Recently, these events have been further examined in vivo with the use of 
liposome-encapsulated dichloromethylene diphosphate (Cl2-MDP-lp) to selectively 
destroy the macrophages. Selective depletion of testicular macrophages in young rats 
during pubertal develpment [Gaytan et al, 1994a] or in adult rats treated with ethane 
dimethane sulphonate ^DS) to selectively destroy the Leydig cell [Gaytan et al, 
1994b，1994c] resulted in a delay in the differentiation, development and proliferation 
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of the Leydig cells. Therefore, cytokines from testicular macrophages (notably JLA, 
TNF and TGF) are considered to be important in stimulating the differentiation and 
development of immature Leydig cells or Leydig cell precursors into mature adult 
Leydig cells. Conversely, rats that had the testicular macrophages selectively 
removed by intratesticular Cl2-MDP-lp injection would show a delay in re-populating 
the interstitium when the Leydig cells were also destroyed by EDS [Gaytan—d al, — 
1994b]. These data again point to a role for Leydig cell in controlling the testicular 
macrophage population. 
- Despite strong evidence for macrophage involvement in the local control of 
testicular function, the origin ofthis cell type in the testis remains unclear. It has been 
proposed that testicular macrophages may arise from the recruitment ofbone marrow-
derived monocytes from the circulation or from the proliferation of existing cells 
within the interstitium. In relation to the first notion, it is of interest to note VEGF 
secreted from Leydig cells [Au et al, 1997] and VEGF receptors (flt-1) present on 
testicular macrophages [Laslett et al, 1997] could mediate this process. Using a 
chemotaxis chamber, Au et al [1998] have been able to demonstrate that in vitro, 
VEGF can induce the migration of rat testicular macrophages in a dose dependent 
manner. These findings are similar to the one reported on the chemotactic effect of 
VEGF on human monocytes, which appears to be acting through VEGF binding to 
flt-1 pBarleon et al, 1996]. 
In view of the reciprocal interaction between Leydig cells and testicular 
macrophages, it is therefore of interest to examine whether testicular macrophage-
derived cytokines or growth factors could be involved in the regulation ofVEGF gene 
expression in Leydig cells. 
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1.5 Aims of the present study 
In order to better elucidate the function of VEGF in the testis, it is important 
to understand how the expression of this growth factor is being regulated in this 
organ. So, the overall aim of this project is to use the technique of Northern blot 
analysis to examine the regulation of VEGF gene expression in the testis. The study 
- i nvo lved the use ofclonal cell lines ofLeydig cells and Sertoli cells as it would allow 
the regulation in these two major cellular sources of VEGF in the testis to be 
differentiated. At the same time, whole animal experiments would be performed 
where appropriate to relate VEGF mRNA levels in testicular tissues to in vitro 
responses. In the present studies, the first goal was to establish whether the universal 
observation of a hypoxic induction of VEGF expression could similarly be 
demonstrated in the testicular cells, and whether cobalt ions could mimick such an 
effect. Furthermore, it would be highly relevant if a connection could be established 
between the hypoxic effect and the pathophysiology oftesticular ischaemia caused by 
spermatic cord torsion. Secondly, in view of the fact that cadmium is a transition 
metal like cobalt and it has a marked effect in causing permeability increase in the 
testicular vasculature, it would be of interest to determine whether the vascular 
hyperpermeability could be related to an upregulation of VEGF expression by 
cadmium, and whether glucocorticoids - a negative regulator of VEGF, could offer 
protection against the cadmium-induced testicular toxicity. Thirdly, it is important to 
establish for an endocrine organ like the testis, whether VEGF expression would be 
regulated by hormones as in the case of the ovary under the effect of LH/hCG, and 
what second messenger systems are involved. Finally, in view of a significant local 
interaction between Leydig cells and testicular macrophages, and the recent 
demonstration of a possible VEGF action in the recruitment of testicular 
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macrophages, it is highly relevant to determine whether macrophage-derived 
cytokines and growth factors would have any effects on VEGF mRNA expression in 
the Leydig cells. 
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2. Afaterials and methods 
2.1 Animals 
Adult male Sprague-Dawley rats (400-450g) were obtained from the 
Laboratory Animal Services Center, The Chinese University of Hong Kong. They 
were kept under an environment of controlled temperature (21±2�C)�humidity (below 
75%), and light-dark cycle [12h light (06:00h-18:00h) / 12h dark (18:00h-06:00h]. 
The animals had free access to water and standard rat chow ad lihitum. All 
- procedures performed on the animals had been approved by the Animal Care and Use 
Committee ofThe Chinese University ofHong Kong. 
2.1.1 Spermatic cord torsion 
Spermatic cord torsion occurs spontaneously in men [Smith-Harrison & 
Koontz, 1990]. This condition can be experimentally induced in animals, and the 
resulting ischaemia was used in the present study to create the situation ofhypoxia in 
the testis. In view of the fact that unilateral spermatic cord torsion may have 
detrimental effect on the contralateral untreated testis [Sarica et aL, 1997; Salman et 
al.’ 1998; Nguyen et aL, 1998]�the present procedure was performed bilaterally on 
both testes in the treatment group. The control animals were age-matched and 
received the sham-operation. Spermatic cord torsion was used in place of testicular 
torsion since in pilot experiments, it gave a higher success rate in producing gross 
morphological appearance ofischaemia in the testes. 
Spermatic cord torsion was performed according to the procedure described 
by Tumer et aL [1996]. Animals were placed under ether anaesthesia, and the testes 
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were exteriorized through two separate scrotal incisions. After cutting the 
gubemaculum, the spermatic cord was rotated clockwise through 720 degrees, and 
the position of the testis was fixed by passing two sutures (5-0 black silk) through the 
.testicular capsule (one on the side and the other at the base) and attaching to the wall 
of the scrotum. In the sham-operated control, the gubemaculum was cut and the 
spermatic cord was rotated through 720 degrees before the torsion was immediately 
undone in less than 30 seconds. Once the testis was returned to its original position, 
it was again fixed by suturing the capsule to the wall of the scrotum at two positions. 
The incisions through the scrotum and the skin were closed separately using 3-0 silk 
suture. The rats were allowed to recover from the anaesthesia, and the effect of 
spermatic cord torsion was examined 6 hours after treatment when the animals were 
killed by asphyxiation using carbon dioxide. Before removing the testes, the 
spermatic cord torsion was checked to ensure that it had been maintained at 720 
degrees. Those testes found to have an anomalous blood supply were excluded from 
the study. After removing the capsule, the testis was divided roughly into 4 equal 
portions which were then placed separately into 1.5 ml microcentrifuge tubes and 
snap frozen in liquid nitrogen. The testis samples were stored at -80°C for less than 2 
weeks before total RNA was isolated. 
2.1.2 Cadmium chloride treatment 
Rats were given a single intraperitoneal injection of cadmium chloride (CdCl2, 
6 mgy'kg body weight) fBDH, England) or saline alone for the control，and studied at 
6 and 12 hours post-injection. At the end of treatment, the animals were killed by 
decapitation, and the testes were harvested following the same procedure as described 
above and rapidly frozen in liquid nitrogen. The testicular tissues were stored at -80° 
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C until for the extraction of total RNA. 
2.1.3 Leydig cell depletion and cadmium chloride treatment 
Ethane-1,2-dimethane sulphonate (EDS) is not commercially available and 
was synthesized by the Chemistry Department, The Chinese University of Hong 
Kong, following the —procedure described by Jackson & Jackson [1984], and 
Rommerts [1985]. EDS was made up just before use in a dimethylsulphoxide : water 
mixture QZ)MSO:H2O, 1:3, v/v) at a concentration of 75 mg/ml. Rats were 
administered a single intraperitoneal injection of EDS (75 mg/kg body weight) or the 
vehicle ^)MSO:water) 3 days prior to receiving a single intraperitoneal injection of 
CdCl2 (6 mg/kg body weight) or saline for the sham-treated control, and studied 6 
hours after the CdCl2 injection. The rats were killed by decapitation, and the testes 
were collected and kept frozen at -80�C until for the extraction of total RNA. 
2.1.4 Dexamethasone pretreatment and cadmium chloride injection 
Dexamethasone (Sigma, St. Louis, MO, USA) was suspended in com oil at a 
concentration of 1 mg/ml. Adult rats were given daily subcutaneous injection of 
dexamethasone (1 mg/kg body weight) for four consecutive days. One hour after the last 
injection, a single dose of CdCl2 (6 mg/kg body weight, i.p.) was given and the animals 
were killed 6 hours p0st-CdCl2 injection by decapitation. The right testes were 
removed, quartered and snap frozen in liquid nitrogen for the collection of total RNA 
a later stage. The left testes were perfusion fixed and processed for 
immunohistochemical staining (to be detailed later). 
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2.1.5 hCG injection 
Human chorionic gonadotrophin (hCG, 5,000 KJ/ampoule, Pregnyl, Organon, 
Netherland) was reconstituted in phosphate-buffered saline (PBS, pH 7.4) containing 
0.1% bovine serum albumin to a concentration of 500 KJ/ml. Each adult rat was 
injected subcutaneously with 100 KJ hCG (or saHne for the control) and testes were 
coUected after 24 hours. 
2.2 Immunohistochemistry 
2.2.1 Perfusion fixation of the testes 
The testis was excised from the animal after it was freed from the epididymis. 
Using a scapel blade (size #24, Swann-Morton, Sheffield，England), a small cut was 
made in the testicular subcapsular artery along its course down the epididymal margin 
of the testis and close to where it enters the tunica albuginea at the cranial pole of the 
testis. A cannula constructed from a polythene tubing (0.5 mm i.d., 1.0 mm o.d., 
800/110/160，Portex, UK) and heat-drawn to a tip diameter of about 100 ^m 
diameter was inserted into the subcapsular artery along the direction of normal blood 
flow. Pre-warmed (25-30°C) heparinized saline (50 U/ml of a sodium salt of heparin 
from porcine intestinal mucosa in normal saline; Sigma, USA) was infused into the 
testis by hand using a 5 ml syringe fitted with a gauge 23 needle (Terumo, Tokyo, 
Japan). Care was taken to prevent the entry of air bubbles. The volume of infusate 
(1-3 ml) was adjusted until there was a complete removal of blood. Following the 
saline infusion, 1.5-2.0 ml ofBouin fixative was infused until it distributed uniformly 
throughout the testis. 
After the initial fixation by perfusion, the perfused testis was immersion-fixed 
in Bouin solution for 24 hours at room temperature, followed by another 24 hours at 
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4°C. After the first 24 hours, the testis was cut using a microtome blade (S35, 
Feather, Japan) into 2 mm thick slices at right angle to its cranial-caudal axis. 
2.2.2 Processing of the testes for histological section 
After fixation，the testes were transferred to 70% ethanol and washed 4-5 
times to remove the picric acid left from the Bouin fixative. A slice of tissue (about 2 
mm thick) was taken from the central part of each testis and put through a tissue 
processor (Department of Anatomy, The Chinese University of Hong Kong) for 
. dehydration in alcohol, clearing in xylene and embedding in paraplast (Paraplast X-
TRA, melting point 50-54°C, Oxford Labware，St. Louis, MO, USA). The timings 
of the above steps were as follow: 80% ethanol (2 hours), 95% ethanol (2 hours), 3 
changes of 100% ethanol (1 hour each); 2 changes of xylene (1 hour each) and 2 
changes ofParaplast X-TRA (1½ hours each). Five-micron sections were cut using a 
microtome QModel 1130，Biocut, Reichert-Jung, Germany) and mounted on glass 
slides coated with 1% 3-aminopropyltriethoxysilane (APES) (Sigma, St Louis, MO, 
USA) in ethanol (Maddox & Jenkins, 1987). 
2.2.3 Immunohistochemical staining for VEGF 
When studying the effect of cadmium on vascular permeability changes and 
VEGF expression in the testis, the tissue histology and VEGF immunoreactivity were 
also examined in testis sections after immunohistochemical staining. 
Reagents used for immunohistochemical staining are from Zymed Laboratories 
Inc. (South San Francisco, USA) and they are based on the streptavidin-biotin-
peroxidase method. The procedure was carried out according to the manufacturer's 
instructions with some modifications. Five microns testis sections were dewaxed in 
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two changes of (R)-(+)-limonen (Merck, Germany) (4 minutes each)，rehydrated 
through a down-series of ethanol (2 changes of 4 minutes each in absolute ethanol，1 
wash for 2 minutes in 70% ethanol), placed for 5 minutes in distilled water, and finally 
.equilibrated in 10 mM phosphate-buffer saline (PBS, pH 7.4). The tissue endogenous 
peroxidase activity was quenched by treatment with 3% H2O2 (Merck, Germany) in 
PBS for 10 minutes. 
Before reacting with the VEGF antibody, the testis sections were further 
subjected to an antigen retrieval procedure to unmask the antigenic sites for antibody 
. binding. The slides were heated in 0.01 M citrate buffer (pH 4.1) for 20 min at 95�C 
and then left to cool in the same buffer for 20 min at room temperature. 
The VEGF antibody used was commercially available (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). It is an affinity-purified rabbit polyclonal 
antibody raised against the first 20 amino acids in the N-terminal of VEGF, which are 
common among the different isoforms. It was used at 1:200 dilution in PBS 
containing 20% fetal calf serum (FCS) (Gibco BRL, Grand Island, NY, USA). The 
incubation was carried out for 1 hour at room temperature, after which the VEGF 
antibody was rinsed off and replaced by the biotinylated secondary antibody (goat 
anti-rabbit IgG) used at 1:75 dilution for 10 minutes at room temperature. In between 
steps, the sections were rinsed three times at 2-minute intervals with PBS. Following 
reaction with the second antibody, peroxidase-conjugated streptavidin (diluted 1:400 
in PBS) was added and left for 10 minutes at room temperature. Finally, specific 
staining of the antigen was visualized by the addition of the chromogen - the AEC 
reagent, which gave a red colour after 15-30 minutes incubation at room temperature. 
After immunostaining, the sections were counterstained with haematoxylin and 
mounted without dehydration in an aqueous mountant (polyvinyl pyrrolidone). 
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2.2.4 Photomicrograph 
The immunostaining was examined under light microscopy (Optiphot-2, 
Nikon, Japan) and areas of interest were recorded on photographic slides (Kodak 
EPN slide film) using a photographic system ^Vlicroflex, Nikon) with automatic 
exposure. — — 
2.3 Cell cultures 
2.3.1 Cell lines of mouse TM3 Leydig cells and TM4 Sertoli cells 
TM3 Leydig cells and TM4 Sertoli cells were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). They are both clonal cell 
lines derived from ICR mice. Both cell types were cultured in 1:1 Dulbecco Modified 
Eagle Medium (DMEM):Ham F12 Medium (Gibco BRL, Grand Island, NY, USA; 
Cat. No. 12500-039) supplemented with 1.2 gA sodium bicarbonate QVlerck, 
Darmstadt, Germany), 4.5 gA glucose (Boehringer Mannheim, Germany), 15 mM 
HEPES (Boehringer Mannheim, Germany), 10 units/ml penicillin G sodium and 10 
^ig/ml streptomycin sulphate (Gibco BRL, Grand Island, NY, USA), 5% horse serum 
(Gibco BRL, Grand Island, NY, USA) and 2.5% foetal calf serum (Gibco BRL, 
Grand Island, NY, USA). They were grown in tissue culture dishes (100 x 20 mm; 
Falcon, Becton Dickinson Labware, Franklin Lakes, NJ, USA) which were kept in a 
water-jacketed CO2 incubator Q^uaire, Techcomp) maintained at 37°C under a 
humidified atmosphere of 5% CO2 in air. The medium was changed every 3 days, and 
the cells were passaged at a dilution ratio ofl:5 at 3-5 days intervals. 
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2.3.2 Tumour cell line of mouse MLTC-1 Leydig cells 
A tumor cell line of mouse Leydig cells QVDLTC-1) was obtained from the 
American Type Culture Collection (ATCC, Manassas, VA, USA). Based on 
information provided by the supplier and other published studies [Panesar, 1999], this 
cell line is known to retain its LH responsiveness despite being passaged repeatedly in 
culture. The cells were grown in tissue culture dishes (100 x 20 mm; Falcon, Becton 
Dickinson Labware, Franklin Lakes, NJ, USA) containing RPMI 1640 medium 
buffered with 25 mM HEPES (Gibco BRL, Grand Island, NY, USA; Cat. No. 
23400-013). The medium had 10 units/ml penicillin G sodium and 10 n,g/ml 
streptomycin sulphate (Gibco BRL, Grand Island, NY, USA) added as antibiotics and 
was supplemented with 10% fetal bovine serum (Gibco BRL, Grand Island, NY, 
USA). The cells were kept at 37°C under a humidified atmosphere of 5% CO2 in air. 
The medium was changed every 3 days and the cells were passaged at 1:3 dilution 
after a period of 5-6 days. 
2.4 Cell treatments 
After the cells reached 90% confluence, the culture medium was changed to 
serum-free and the cells were left for 24 hours under this condition prior to the 
initiation of any treatment. The procedure was aimed at synchronizing the activities 
of the cells, which supposedly would include the basal expression of VEGF. Cells 
grown under serum-free condition for 24 hours showed no morphologic changes 
under phase contrast light microscopy, and no decrease in their percentages (>98%) 
to exclude the trypan blue dye (Sigma, St. Louis, MO, USA). Also they could 
subsequently be passaged normally. 
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At the start of treatment, the medium was changed and serum was added back 
to the cells. Each treatment was performed in duplicate using two dishes of cells 
which were subsequently harvested and pooled together for the extraction of total 
RNA. In most studies, the experiment was repeated at least three times under 
identical conditions and using the same batch of reagents and drugs. All comparisons 
were made against the control that was derived from the same passage and cultured 
for the same period without being exposed to treatment. The various tested 
substances were examined first for their time dependent effect at concentrations that 
were based on published studies and would supposedly produce the maximum effect. 
After establishing when the response was maximum, this particular time point was 
used in the study of the concentration dependent effect. 
At the end of treatment, the cells were harvested by trypsinization after the 
medium was pippetted off and replaced with a 0.25% t^psin (Gibco BRL, Grand 
Island, NY, USA) solution in phosphate-buffered saline. Subsequently, the cells were 
pelleted by low speed centrifugation (300 g for 5 minutes) and washed twice with 
serum-free medium before RNA lysis buffer (Qiagen, Santa Clarita，CA, USA) was 
added for the extraction of total RNA. 
2.4.1 Hypoxic treatment 
Effect of hypoxia 
"Normoxic condition" refers to the standard cell culture condition under a 
humidified atmosphere of 5% CO2 in air (estimated to contain 21% O2 and 74% N2). 
Hypoxia was induced by placing the cells in a custom-made humidified chamber which 
was gassed with a special air mixture containing 1% O2, 5% CO2 and 94% N2 O^ong 
Kong Oxygen, Tseung Kwan 0，Hong Kong). The gas composition was based on 
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earlier published studies on VEGF [Goldberg and Schneider, 1994; Gleadle et al., 
1995; Levy et al.，1996]. The chamber was in tum placed inside an incubator (Jouan 
RB115, Winchester, VA, USA) to maintain the cells at 37 °C. 
In the present study, TM3 and TM4 cell lines were exposed to the hypoxic 
treatment for various time intervals ranging from 1 to 24 hours. The corresponding 
controls were derived from the same passage and cultured under normoxic condition 
for the same period. At each time point, cells were harvested by trypsinization. Then 
they were washed twice with serum-free medium followed by the addition of lysis 
buffer (Qiagen, Santa Clarita, CA, USA) for the extraction oftotal RNA. 
Effect of cobalt chloride 
Previous studies indicated that cobalt chloride (C0Cl2) could mimick the effect 
of hypoxia in inducing an upregulation of VEGF expression, and the maximum effect 
was observed at 300 p,m concentration in human hepatoma cell line, Hep3B 
[Goldberg and Schneider, 1994]. In the present study, the same concentration of 
C0Cl2 (BDH, England) was tested for its time dependent effect in stimulating a rise in 
VEGF mRNA levels in TM3 and TM4 cells. A stock solution of 10 mM C0Cl2 was 
made up in distilled water and added to the culture medium to reach the desired 
concentration. The time intervals chosen for this study were identical to those of the 
hypoxic treatment. The control cultures were incubated for the same period without 
the addition of C0Cl2. Based on when the maximum effect was observed, the 
concentration-dependent effect of C0Cl2 was examined over a range of 3 to 600 i^M. 
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Effects of NO donors and NOS inhibitor 
Sodium nitroprusside (SNP), S-nitroso-N-acetylpenicillamine (SNAP), N^-
nitro-L-arginine methyl ester hydrochloride OL-NAME), and N^-nitro-D-Arginine 
methyl ester hydrochloride (D-NAME) were obtained from Research Biochemicals 
International (RBI, Natick, MA, USA). They were made up on the day of use in 
culture medium. SNP and SNAP are nitric oxide QS[0) donors, L-NAME is a nitric 
oxide synthase pvFOS) inhibitor and D-NAME is the inactive analogue of L-NAME. 
TM3 cells were treated with SNP, SNAP, L-NAME or D-NAME for 6 hours under 
normoxic or hypoxic condition to study the possible interaction between NO and 
hypoxia in controlling VEGF gene expression. 
2.4.2 Cadmium chloride treatment 
Effect of cadmium chloride (CdCh) 
In order to differentiate the effect of cadmium on the two major cell types 
expressing VEGF in the testes, in vitro studies were performed using TM3 Leydig 
cells and TM4 Sertoli cells. Both the time- and concentration-dependent effects of 
cadmium were examined similar to those earlier described in the study using C0Cl2r 
The time intervals chosen for the two studies were identical though lower 
concentrations of CdCl2 were tested [Eyssen-Hemandez et al, 1996]. 
Dexamethasone and cadmium chloride treatment 
Dexamethasone (Sigma, St. Louis, MO, USA) was dissolved in absolute 
ethanol to give a 20 mM stock solution which was stored at -20°C until use. When 
tested on TM3 cells, dexamethasone was added to the cell culture to give a final 
concentration 1 i^M (or 0.005% ethanol for the vehicle-treated control) before CdCl2 
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(or saline for the correponding control) was added, and the effects examined 
following a 6-hour treatment period. 
2.4.3 hCG treatment 
Human chorionic gonadotrophin (hCG, Pregnyl, Organon, Netherland) was 
prepared in phosphate-buffered saline (PBS) with 0.1% bovine serum albumin 
(Fraction V，protease-free; Sigma Chemicals Co., St. Louis, MO, USA) added as the 
carrier protein. Its time-dependent effect was examined in TM3 and MLTC-1 cells at 
a final concentration of 1 RJ/ml. Since only the latter cell type gave a response，the 
concentration-dependent effect was subsequently only examined in MLTC-1 cells. 
2.4.4 Activators of second messenger systems 
Effecf offorskolin 
Forskolin (Sigma, St. Louis, MO, USA) is an activator of adenylate cyclase. 
It was dissolved in DMSO (Sigma, St. Louis, MO, USA) to give a 20 mM stock 
solution which was stored at -20°C until use. Its time- and concentration-effects on 
VEGF mRNA expression were examined in both TM3 and TM4 cells. The 
corresponding time controls were cultured without treatment for the same periods. 
Effect of 8-(4-chlorophenylthio)-cAMP sodium 
8-(4-chlorophenylthio)-cAMP sodium was purchased from Research 
Biochemicals International QRJBI, Natick, MA, USA). It is a cell permeable synthetic 
analogue of cAMP. It was dissolved in culture medium to give a 0.5 M stock solution 
that could be stored at -20°C for three months without detectable loss of activity. Its 
time-dependent effect on TM3 cells was examined at a final concentration of 1 mM. 
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Effect ofphorbol 12-myristate 13-acetate (PMA) 
PMA (Research Biochemicals Inc., Natick, MA, USA) is a potent activator of 
protein kinase C. It was dissolved in DMSO (Sigma, St. Louis, MO, USA) to give a 
2 mM stock solution which was then stored at -20°C until use. Its time- and 
concentration-dependent effects on VEGF mRNA expression were examined in both 
TM3 and TM4 cells. The corresponding time controls were cultured for the same 
treatment periods in the absence ofPMA. 
2.4.5 Effects of pro-inflammatory cytokines and angiogenic growth factors 
Pro-inflammatory cytokines 
Recombinant murine interleukin 1 alpha (n>-la), murine interleukin 1 beta 
(EL-lp), human tumor necrosis factor alpha (TNP-a), and human tumor necrosis 
factor beta (TNF-P) were obtained from R&D Systems Inc (Minneapolis, USA). 
They were constituted in phosphate-buffered saline containing 2% fetal bovine serum 
to give stock solutions of 10 p,g/ml, which were then snap frozen and stored at -80°C. 
Recombinant murine interleukin-6 (EL-6) was purchased from Pepro Tech EG 
Ltd. (London, England). It was reconstituted in water to give a stock solution of 100 
^ig/ml, which was then aliquotted, snap frozen and stored at -80°C. 
These cytokines were first examined for their time-dependent efFect^ on 
VEGF mRNA expression in TM3 cells at a fixed concentration of 10 ng/ml. Those 
which were shown to have an effect would be further examined for the dose-
dependency using different concentrations ofthe peptides. 
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bFGFand TGF-/31 treatment 
Human recombinant basic fibroblast growth factor (bFGF) was obtained from 
R&D Systems Inc. (Minneapolis, USA), and reconstituted in phosphate-buffered 
saline containing 2% fetal bovine serum to give a stock solution of 25 ^ig/ml 
concentration. This was then aliquoted, snap frozen and stored at -80°C. Human 
recombinant transforming growth factor-pl (TGF-pi) was purchased from 
Calbiochem-Novabiochem Corporation (Canada) and reconstituted in 4mM HC1 
containing 2% fetal bovine serum to give a stock solution of 2 |ig/ml. This was then 
aliquoted and stored frozen at -80°C. These two growth factors were tested for their 
time- and concentration-dependent effects on VEGF mRNA expression in TM3 cells. 
2.5 Preparation of cDNA probes 
2.5.1 VEGF cDNA probe preparation 
VEGF cDNA probe was prepared by reverse transcription and polymerase 
chain reaction (RT-PCR) using total RNA from TM3 cells as the template and a pair 
ofspecific primers; sense primer: 5'-CTGCTCTCTTGGGTGCAC-3' (nucleotides 14-
31) and antisense primer: 5'-GCAAGTACGTTCGTTTAACTC-3' (nucleotides 533 to 
553) (GenBank Accession No: M32167). These primers were designed based on 
published rat VEGF cDNA sequences. 
An extract of total RNA (5 i^g) from TM3 cells, 0.5 \ig of reverse primer 
(Oligo dT) and l^il of0.1 MDTT were denatured at 72°C for 10 min and then cooled 
immediately. Superscript II reverse transcriptase (200 units) (Gibco BRL, Grand 
Island, NY, USA) was added to the RNA together with 5x first strand buffer and 
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lOmM of dNTPs to a total volume of20 [il Reverse transcription was performed at 
42°C for 50 minutes, followed by a final extension time of 15 minutes at 72°C. The 
cDNA was then stored at -20°C until use. 
Before performing the PCR amplification, the reaction conditions had been 
optimized for the incubation time, temperature, and concentrations of Taq 
polymerase, primers, MgCb, and cDNA template. 
The PCR reaction mixture contained 5 i^l lOxPCR buffer, 1 i^l of 10 mM 
dNTPs, 1.5 mM MgCl2, 1 ^1 of cDNA template, and 1 i^l of sense and antisense 
primers (15 pmol). It was heated to 94�C for 5 minutes to completely denature the 
template before adding 1 [i\ 0.5 unit Taq polymerase (Gibco BRL, Grand Island, NY, 
USA), and made to a final volume of 50 i^l. The PCR reaction was carried in a DNA 
thermal cycler ^Peltier Thermal Cycler, PTC-200, MJ Research, San Fancisco, USA) 
for 35 cycles: 94�C for 1 minute followed by 55°C for 1 min 30 secs and 72°C for 2 
minutes. Afler these, there was a cycle of final extension at 72°C for 10 minutes, and 
the reaction was terminated and the products kept at 4°C. 
PCR products were separated by electrophoresis in 2% agarose gel 
(electrophoresis grade, Gibco BRL, Grand Island, NY, USA) containing 0.5 mg/ml 
ethidium bromide in TAE buffer (40 mM Tris, 20 mM Na acetate, 1 mM EDTA, pH 
7.2) and visualized under ultra violet (UV) light. The band of the correct size, as 
determined by comparison with DNA molecular weight markers^Gibco BRL, Grand 
Island, NY, USA) was cut from the gel and purified by a Gene-Clean kit (BIO 101 
Inc). 
Figure 2.1 shows the separation of the VEGF cDNA probe prepared by PCR 
on an ethidium bromide-stained agarose gel. The major band in lane 1 to 4 shows the 
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DNA mass ladder 
100 bpDNAladder 
— ^ ^ -
^ ^ ^ m 
Lane 1 to 4: VEGF. 
Lane 5 & 6 : Control without addition of template. 
PCR condition: 94�C 1 min; 55�C lmin 30 sec; 72�C 2 min for 35 cycles. 
Primers: Up stream: 5‘-CTGCTCTCTTGGGTGCAC-3 ‘ (nt. 14-31) 
Down stream: 5'-GCAAGTACGTTCGTTTAACTC-3‘ (nt. 533-553) 
(GenBank Accession No.: M32167) 
Figure 2.1 VEGF cDNA probe preparation. PCR products were separated on 
an ethidium bromide-stained agarose gel. The major band in lane 1 to 4 shows 
the product of interest which corresponds to the expected size of 540 bps for the 
most abundant form of VEGF transcript - VEGF 164. Its identity was later 
confirmed by DNA sequencing. This probe was prepared by polymerase chain 
reaction using primers designed according to the rat sequence (GenBank' 
Accession No.: M32167) and template from the mouse TM3 cell line. It shows 
97.8% homology to the corresponding VEGF nucleotide sequence in the rat. 
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product of interest that corresponds to the expected size of 540 bps for the most 
abundant form ofVEGF transcript _ VEGFi64. 
2.5.2 P-actin cDNA probe preparation 
p-actin cDNA probe was prepared following similar procedure as earlier 
described for the preparation of VEGF probe. RT was performed using total RNA 
from TM3 cells as the template with another pair of specific primers. The primer 
sequences were as follow: sense primer: 5'-TCACCGAGGCCCCTCTGAACCCTA-3' 
(nucleotides 1642 to 1665); antisense primer: 5'-
GGCAGTAATCTCCTTCTGCATCCT-3' (nucleotides 2814 to 2837) (GenBank 
Accession No: J00691). The PCR amplification was performed in 50 i^l volume using 
a DNA thermal cycler ^Peltier Thermal Cycler, PTC-200, MJ Research, San Fancisco, 
USA) programmed to a different set of conditons from that earlier described for 
VEGF. The amplification was carried out for 30 cycles: 94°C for 1 minute followed 
by 55°C for 1 min 30 secs and 72°C for 2 minutes. The final extension was at 72°C 
for 10 minutes. 
PCR products were separated by electrophoresis in 2% agarose gel containing 
0.5 mgAnl ethidium bromide in TAE buffer (40 mM Tris, 20 mM Na acetate, 1 mM 
EDTA, pH 7.2) and visualized under UV light. The band of the correct size, as 
determined by comparison with DNA^molecular weight markers (Gibco BRL, Grand 
Island, NY, USA) was cut from the gel and purified by a Gene-Clean kit (BIO 101 
Inc). 
Figure 2.2 shows the separation ofthe P-actin cDNA probe prepared by PCR 
on an ethidium bromide-stained agarose gel. The major band corresponding to the 
expected size of 645 bps was purified, radiolabelled and used as the P-actin probe 
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100 bpDNAladder 
I I 1 2 3 4 5 6 
fe"^^^J;^^ g ^ ^ y ^ ^ffl ^ ^^ ^^ g^^ |j||[j^ g^[j^jjjj|^^^||||^J^ ^^ ^^ ^^ |^^|jyj|Pj^ j^^ ^^ ^ 
^^^^^^^^^^^^ i^^  i^^^»s ^ ^^^^ ^^ ^^ p^fpy^fj^ j^pjj^ s^im^^^ i^^^ _, __ fc^^^^Mmi 645bp 
600 b p ~ • g E j _ _ ^ ^ ^ ^ ^ ^ - i | 04〕叩 
I |^ jj||X^ oooc^ *^c*i^ 2Jg|^  0 X MgQ< pyyy^ fflp3f^ ggggpp9ff^ BB fflBflHflHfPTnnnfTiiiflfl_gpwotooQ^^***^^^^^B^^^^^^^^^^B^^^^gwodBB � EMgw^^^m ^ ^^ Mff>MawBBBWiffffiHiHiMPiliBBi^ f^l^ |_HMI g^^j^Sg^ H^^^^ i^^SSBB8Sm8jBMBIHMMHIBHBI^M^BIBBBmHiMMg^HBI 
fjfgggggjfjj^ffg|^gfjjgjgfgjggggggggggggg|^^^gg^gg^g|||^|^|g|gggg^gfgggggggg^ 
iiiiiMHMB^^B^^^MBBB^HH^HBBBiti8 
ngm^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ i^ mmiiiimi^ mmiiiiii^ m^i^ iiniiumjijmm^ yiyiim 
Lane 1 to 4: P-actin. 
Lane 5 & 6 : Control without addition of template. 
PCR condition: 94�C 1 min; 55�C 1 min 30 sec; 72�C 2 min for 30 cycles. 
Primers: Up stream: 5'-TCACCGAGGCCCCTCTGAACCCTA-3' (nt. 1642-1665) 
Down stream: 5'-GGCAGTAATCTCCTTCTGCATCCT-3'(nt. 2814-2837) 
(GenBank Accession No.: J00691) 
Figure 2.2 P-actin cDNA probe preparation. The products of the PCR 
reaction were separated on ethidium bromide-stained agarose gel and the major 
band corresponding to the expected size of 645 bps was radiolabelled and used 
as the P-actin probe after its identity was confirmed by DNA sequencing. This 
probe was prepared by polymerase chain reaction using primers designed 
according to the rat sequence (GenBank Accession No.: J00691) and template" 
from the mouse TM3 cell line. It shows 96.4% sequence homology to the 
corresponding region of the rat P-actin DNA sequence. 
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after its identity was also confirmed by DNA sequencing. 
2.5.3 Purification of PCR products 
The DNA band was excised from the ethidium bromide-stained agarose gel 
using a scapel blade (size #24，Swann-Morton, Sheffield, England) under long-wave 
XJV light. The agarose was then weighed and put into a tube with 3 volumes (1 mUg 
of gel) of sodium iodide solution added. The tube with its content was incubated at 
55°C for 5 minutes or until the agarose had completely dissolved. The soluble 
agarose was transferred to a 1.5 ml microcentrifuge tube and 5 i^l of GLASSMELK® 
suspension from the Gene-Clean kit (BIO 101 Inc) was added. The GLASSMKK® 
contains a specially formulated silica matrix that binds single and double stranded 
DNA but not other contaminants. After vortexing to mix the content, the tube was 
placed on ice for 15 minutes to allow the binding ofDNA to the silica matrix. During 
this reaction, mixing was performed every 1-2 minutes to ensure that GLASSMK.K® 
stayed suspended. The reaction was terminated by a brief centrifugation for 
approximately five seconds to separate the GLASSMH^K®. The supematant was then 
discarded and the pellet was washed 3 times, each with 500 i^l of *New Wash 
Solution,. The pellet was resuspended in 20 pil of diethylpyrocarbonate (DEPC)-
treated H2O and incubated at 55°C for 5 minutes. At the end, the pellet was spun 
down for 30 secs, and the supematant containing the eluted DNA was collected. 
After purification using the Gene-Clean Kit II, the PCR product was again run on 2% 
agarose gel and its concentration was estimated by comparing against a DNA mass 
ladder (Gibco BRL, Grand Island, NY, USA). The authenicity of isolated product 
was later confirmed by DNA sequencing. 
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2.5.4 Confirmation of PCR Products 
The sequencing mixture contained 50 ng ofPCR product (i.e. the template), 
3.2 pmole of upstream primer, 8 i^l of Terminator Ready Reaction Mix 
(deRhodamine) ^>E Bio Systems，California, USA) and DEPC-treated H2O in 20 i^L 
It was heated to 96°C for 3 minutes and was performed in a DNA thermal cycler 
(Peltier Thermal Cycler, PTC-200, MJ Research, San Fancisco, USA) for 25 cycles 
under the following conditions: 96°C for 1 minute followed by 50°C for 1 minute and 
60�C for 4 minutes. At the end，the reaction product was loaded into a Micro Bio-
Gel P-30 (Bio-rad) column and centrifuged at 5,000 g for 4 minutes in order to 
remove free nucleotides and primer. The fraction collected was mixed well with an 
equal volume of Template Suppression Reagent (TSR) buffer and incubated at 95°C 
for 2 minutes. Finally, the tube was quickly chilled on ice, and the content was 
analyzed using an automated DNA sequencer (Advanced ABI 310 Genetic Analyzer, 
Perkin-Elmer, Tokyo, Japan). 
The sequencing data obtained were submitted to the BLAST Sequence 
Similarity Search QSFCBI，National Centre for Biotechnology Informatiorr; 
http://www.ncbi.nlm.nih.gov/BLAST), and in both cases, the authenticity of VEGF 
and P-actin probes was confirmed. Though the analyses did not yield the entire 
sequence of the two probes, nevertheless based on published sequence available from 
GenBank, these probes which were prepared using cDNA from a mouse cell line as 
the template would show 97.8% and 96.4% homology to the corresponding regions 
of the rat VEGF and P-actin nucleotide sequence, respectively. 
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2.5.5 cDNA Probe labeling 
" ^ ) 
The cDNA probes were labelled with [a- P]dCTP (Amersham, 
Buckinghamshire, UK) by the method of the random priming using Rediprime DNA 
labelling kit (Amersham, Buckinghamshire, UK) (Figure 2.3). The reaction product 
was purified and cleared of unincorporated nucleotides using Nuc-Trap column from 
Stratagene. 
According to the manufacturer's instructions, the cDNA probe was denatured 
by heating to 95-100°C in a boiling water bath for 10 minutes without snap cooling 
on ice after this step. The probe was then diluted to a concentration of 50 ng in 45|il 
ofDEPC-treated H2O and was added to the labeling mix (containing buffered solution 
of dATP, dGTP, dTTP, exonuclease free Kknow enzyme and radom primers in a 
dried, stabilised form). The reaction tube was quickly mix by gently flicking the tube. 
After a brief centrifugation to bring the content to the bottom of the tube, 5 ^1 of ^^P-
labelled dCTP (-50 p,Ci) was added and mixed by gently pipetting up and down five 
times. The reaction was.incubated at 37°C for 10 minutes, and then stopped by 
adding 5 [i\ of 0.2 M EDTA. The labelled probe was purified by passing through the 
Nuc-Trap column (Stratagene) and washed with 2x 100 |il STE buffer (100 mM 
NaCl, 20 mM Tris-HCl, pH7.5, 10 mM EDTA) and collected the eluent in a 
microcentrifuge tube. The final volume was made up to 1 ml with STE buffer and the 
labelled probe^was counted with a radioactive counter (Model QC2000, Bioscan Inc., 
Washington, USA). The probes should have specific activities of 6-10 x 10^  cpm/mI. 
2.6 RNA extraction 
2.6.1 Extraction of total RNA from testicular cell lines 
Total cellular RNA was isolated from cell lysates of testicular cell lines using 
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Figure 2.3 Preparation of p^P]-dCTP-labelled cDNA probes using Amersham's 
Rediprime DNA labelling system. 
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the Qiagen RNeasy RNA isolation kit (Qiagen, Santa Clarita, CA, USA) (Figure 2.4)， 
according to the manufacturer's instructions. This technology combines the selective 
binding properties of a silica-gel-based membrane with the speed of microspin 
technology. A specialized high-salt buffer system allows up to 100 ^g of total RNA 
longer than 200 bases to bind to the RNeasy silica-gel membrane. 
Ribonucleases ^CNases) are very stable and active enzymes that generally do 
not require cofactors to function. Since they are difficult to inactivate and only 
minute amounts are sufficient to destroy RNA, the following precautions were taken 
during the handling RNA. These include wearing latex or vinyl gloves while handing 
reagents and RNA samples，reserving a bench area for RNA work, wiping the bench 
surface with RNase inhibitor ORNase-free, Gibco BRL, Grand Island, NY, USA), and 
using chemicals suitable for RNA work. 
The RNA extraction was performed at room temperature and all steps were 
completed as quickly as possible. Cells grown in monolayer were collected after 
trypsinization (0.25% trypsin), washing twice with serum-free medium and 
centrifugation to form a pellet. To each cell pellet pooled from two dishes of cells ' 
exposed to the same treatment, 1 ml of guanidinium isothiocyanate (GITC)-containing 
lysis buffer (Qiagen) was added. This buffer also contained 10 i^l of P_ 
mercaptoethanol (Gibco BRL, Grand Island, NY, USA) which was addedjust prior to 
use. The lysis of cells and the shearing of the high molecular weight DNA were 
assisted by passing the lysate repeatedly (at least 10 times) in and out a 1 ml sterile 
plastic syringe fitted with a gauge 25 needle (Terumo, Tokyo, Japan). Then the lysate 
(maximum volume of 700 ^il/column) was added to a QIAshredder spin column 
(Qiagen, Santa Clarita, CA, USA) to further break up the cells, and the homogenized 
lysate was collected into a 2 ml tube following centrifugation at 8,000 g for 2 min. To 
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Figure 2.4 Flow Chart showing RNA extraction procedure using TEOzol reagent 
and/or RNeasy Mini Kit (QIAGEN). 
49 
each volume of cell homogenate collected, 1 volume of 70% ethanol was added and 
mixed by pipetting. The sample/ethanol mix was then loaded on to a RNAeasy spin 
column (maximum volume 700 |il) and centrifuged for 2 minutes at 8,000 g. Further 
addition of fresh sample from the homogenate to the same spin column could be 
repeated at least once without fear of over-loading. Using centrifugation (2 minutes 
at 8,000 g) quick washes of the column were performed once with 700 |j,l RW1 buffer 
followed by 2 times with 500 p,l RPE buffer containing 80% ethanol. No residual 
ethanol should be left in the column after the last spin as it would interfere with 
_ subsequent reactions. Finally, the RNA was eluted from the column using 100 ^1 
DEPC-treated water after centrifugation for 1 minute at 8,000 g. If the expected 
yield ofRNAwas above 30 \xg, then the column was further eluted twice with DEPC-
treated water. RNA present in the eluent was precipitated following a 3 hour 
incubation with 2 volumes of ice cold 100% ethanol and 0.1 volume of 3 M sodium 
acetate at -70°C. At the end，the precipitated RNA was separated by high speed 
centrifUgation (10,000 g) at 4�C, washed once with 70% ethanol and then dried for 5-
10 minutes under centrifugation and vacuum suction using the SpeedVac (DNA 
SpeedVac 110，Savant Instruments Inc., NY, USA). The RNA pellet was 
reconstituted in 20 i^l DEPC-treated water and stored at -70°C until use. 
2.6.2 Extraction of total RNA from testicular tissues 
Wherever possible, the right testis was arbitrarily chosen for the extraction of 
total RNA used in the Northern blot analysis. The method involved the combined use 
ofTRIzol reagent (Gibco BRL, Grand Island, NY, USA) and Qiagen RNAeasy Mini 
RNA isolation kit (Qiagen, Santa Clarita, CA, USA), according to the manufacturer's 
instructions ^Figure 2.4). Briefly, about 400 mg of testicular tissue was hand-
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homogenized in 2 ml TRIzol reagent in a glass homogenizer (Kontes Scientific 
Glassware/Instruments, Vineland, NJ, USA) at 4°C for 5 min. The homogenate was 
centrifuged at 12,000 g for 10 minutes at 4。C in an Eppendorf Refrigerated 
Centrifuge ^Eppendorf 5804R, Hamburg, Germany), and the resulting supernatant 
was transferred to a 1.5 ml microcentrifuge tube and left to stand at room temperature 
for 5 min to allow complete dissociation of the nucleoprotein complexes. At the end 
of the incubation, chloroform was added at a volume of 200 ^il per ml of TRIzol 
reagent originally used. The tube was capped and shaken vigorously by hand for 15 
seconds before the content was allowed to settle for 3 min at room temperature. This 
was then subjected to centrifugation at 10,000 g for 15 minutes at 4。C to achieve the 
separation into a lower phenol-chloroform phase (red in colour), a middle interphase, 
and an upper aqueous phase (colourless). The aqueous phase which supposedly 
contained all the RNA was pipetted off into a 1.5 ml microcentrifuge tube and 1 
volume of 70% ethanol was added and mixed by pipetting. The aqueous/ethanol mix 
was then loaded on to a RNeasy spin column (Qiagen, Santa Clarita, CA, USA). The 
rest of the procedure followed the one that was described earlier for the preparation 
o f R N A from testicular cell lysate. 
2.7 Northern blot analysis 
2.7.1 Measurement of total RNA concentration 
Total RNA was used for Northern blot analysis. The concentration and purity 
o f R N A samples were determined by measuring the absorbance at 260nm (A260) and 
280nm (A280) using a spectrophotometer (UV-1201, Shimadzu, Japan), and the ratio 
should be greater than 1.60. Absorbance readings at 260nm measure RNA 
concentration and they should be greater than 0.15 to ensure significance. The RNA 
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concentration (M>g/^ d) was calculated by the following formula: (absorbance reading at 
’ 260nm x dilution faction x 40)/1000. 
2.7.2 RNA gel electrophoresis 
A 5x formaldehyde gel-running buffer was prepared by first dissolving 20.6 g 
— of MOPS (4-morpholine-propanesulfonic acid, Sigma, St. Louis, MO, USA) in 800 
ml DEPC-treated water containing 50 mM sodium acetate (Sigma, St. Louis, MO, 
USA). Ten millilitres of 0.5 M EDTA was then added and the pH was adjusted to 7.0 
. with sodium hydroxide before the final volume was made up to 1 litre using DEPC-
treated H2O. The solution was stored in a dark bottle to protect it against light. 
One percent (1%) agarose gel was prepared by first adding 1 g agarose to 62 
ml DEPC- treated H2O. The agarose was made to dissolve by boiling in a microwave. 
After the solution was cooled to about 60°C，20 ml of 5x running buffer (final 
concentration lx) , 18 ml of formaldehyde (final concentration 2.2 M) ^BDH, 
England) and 2 [x\ of ethidium bromide were added to give a final volume of 100 ml. 
鲁 .1 
RNA samples were made up to a final volume of 20 ^il in an autoclaved 
RNase-free microcentrifuge tube. This was prepared by adding 20 ^ig o f R N A in 4.5 
^il DEPC-treated H2O to 2 [i\ of 5x MOPS (final concentration 0.5x), 3.5 ^il of 
formaldehyde, and 10 \ji\ of deionized formamide (Sigma, St. Louis, MO, USA). 
The RNA samples were denatured by heating for 15 minutes at 65°C, and then 
chilled on ice. To each sample, 2 p.1 of RNA gel loading buffer (Sigma, St. Louis, 
MO, USA) was added, and to the RNA molecular marker (Gibco BRL, Grand Island, 
NY), 1 j j l of ethidium bromide was added. After loading the samples and the marker 
on to the gel, electrophoresis was carried out overnight (for 22-24 hours) under a 
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voltage of 14 volts using l x MOPS as the gel running buffer. 
2.7.3 Transfer o f R N A to membrane 
The gel was rinsed 3 times with DEPC-treated water to remove the 
formaldehyde OBDH, England) and then soaked in 20 x SSC buffer for 45 minutes. 
SSC buffer ( l x ) contains 0.15 M NaCl and 0.015 M sodium citrate at pH 7. The 
RNA was transferred overnight to Hybond >T (Amersham, Buckinghamshire, UK) 
membrane by capillary action. Briefly it involved placing the gel on the level surface 
_ of the transfer stack over a wick made from Whatman 3 M M paper (Whatman, 
England) and kept moist by 20 x SSC. Care was taken not to trap air bubbles 
between the wick and the gel. Then the gel was surrounded with Gladwrap (or 
parafilm) and a sheet of Hybond N^ (Amersham, Buckinghamshire, UK) membrane 
was placed on top of the gel. Again care was taken to remove any air bubbles trapped 
between the gel and the membrane. Three sheets of pre-wetted 3 M M Whatman paper 
were then placed on top ofthe membrane, followed by a stack of paper towels (〜8 cm 
i || 
high) which was weighed down by a glass plate and a 500 g weight. The capillary “ 
transfer was allowed to proceed ovemight at room temperature. 
After transfer, RNA was fixed to the Hybond >T membrane by ultraviolet 
cross linking ^UV Spectrolinker XL 1500，Spectronics Corporation, Laboratory 
Product Sales, Rochester, NY, USA) at 254 nm with the RNA-side-down. The 
membrane (or the blot) was then placed inside plastic wrap and stored at 4°C until 
ready for hybridization. 
2.7.4 Hybridization with [a-^^P]dCTP-Iabelled probes 
The blot was sandwiched between 2 pieces of nylon mesh and placed inside a 
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hybridization bottle (Robbins Scientific Co., California, USA) that had previously 
been rinsed with DEPC-treated water. Approximately 20 ml of rapid-Hyb buffer 
(Amersham, Buckinghamshire, UK) was added to each bottle and the content was 
pre-warmed to 65°C in a hybridization oven (Biometra, Germany) with rotary mixing 
for 30 minutes. 
— [a-32p]dCTP-labelled VEGF or P-actin probe was denatured by boiling for 5 
minutes at 100°C before it was quickly chilled on ice for 2 minutes. For most 
hybridization reactions, 50 ng of the probe was added to the buffer inside the 
_ hybridization bottle and rapid mixing was achieved by inverting the tube 4-5 times. 
Hybridization was carried out at 65°C for 2.5 hours with rotary mixing. At the end, 
the hybridization buffer containing the probe was decanted ofF. 
The non-specific binding of the probe to the membrane was removed by 
washing with SSC solution inside the hybridization tube. Al l the washings were 
carried out at 65°C and the first one was a low-stringency wash using 40 ml 2x SSC 
containing 0.1% sodium dodecyl sulphate (SDS) (Boehringer Mannheim, Germany) 
for 20 minutes. This was then followed by two higher stringency washes (15 minutes 
each) using 50 ml l x SSC with 0.1% SDS. Final washing of the filter was carried out 
using 100 ml l x SSC with 0.1% SDS for 20 minutes in a plastic box placed inside a 
shaking water bath. The membrane was then collected after briefly blotted dry using a 
sheet ofWhatman 3MM paper, and wrapped in plastic sheet. 
2.7.5 Autoradiography and densitometric quantification 
The blot (wrapped in plastic wrap) was placed flat on a Biomax MS scientific 
imaging film (Kodak, Rochester, NY, USA), and the two were sandwiched between 
two BioMax MS intensifying screens (Kodak, Rochester, NY, USA) before being put 
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inside a cassette. Autoradiography was performed at -70°C for a period that 
depended on the levels of radioactivity originating from the positive signals. In most 
cases, it lasted for less than 12 hours. 
After recording the blot on an X-ray film, the signal intensities were quantified 
using the GS-525 Molecular Imager Phosphor Imaging System (Bio-Rad，Hercules, 
~CA^ USA). The steady-state levels of VEGF mRNA signal intensity were quantified 
by densitometry and ratioed against the P-actin mRNA signal using the Molecular 
Analyst software ^Bio-Rad, Hercules, CA, USA) (Figure 2.5). Each membrane was 
. blotted first with the VEGF cDNA probe and then followed by the P-actin cDNA 
probe for the correction ofloading differences. 
2.8 Data and statistical Analysis 
Results were presented as mean±SE with the number of replicate experiments 
given by the value of n. Statistical analyses of data were performed using a 
commercially available software package (SigmaStat Version 4.0 for Windows 95, 丨 
Jandel Scientific Software, San Rafael, CA, USA). Parametric tests were used “ 
wherever possible, unless the data failed in the normality test. For multiple 
comparisons versus a single control group, one-way ANOVA followed by Dunnett 
test was used, and for multiple comparisons among many groups, one-way analysis of 
variance (ANOVA) followed by Student-Newman-Keuls test was used. A 'P' value 
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Figure 2.5 Molecular phosphor imaging system {Biorad, Molecular Lnager GS-
525 system) and its operation. Step 1: Expose radioactive sample to the storage 
phosphor screen inside the sample loading dock to generate a latent image which 
can be quickly scanned. Step 2: The storage phosphor plate is placed inside the 
scanner where the latent image is readout using a fibre optic infra red scanner. 
Step 3: As the storage phosphor screen is being scanned, the data is sent to the 
host computer for display and analysis. Step 4: Once the phosphor screen has 
been scanned, it can be quickly erased using the screen eraser, and is again ready 
for the next exposure. 
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3. i?ESULTS 
3.1 Effect of hypoxia and cobalt chloride treatment on VEGF expression in 
T M 3 and T M 4 cells 
As one of the pilot experiments in the present investigation, VEGF mRNA 
expression in TM3 Leydig cells was shown to be induced by hypoxic treatment, and 
the magnitude of changes could be mimicked by exposing the cells for the same 
period (6 hours) to 300 ^iM cobalt chloride under normoxic condition (Figure 3.1). 
- A more detailed time-course study revealed that the hypoxic induction of 
VEGF mRNA expression in TM3 cells became significant at 3 hours after treatment 
followed by a peaked increase of 2.6-fold above the control at 6 hours, and then 
gradually declined to lower levels at 12 and 24 hours after treatment (Figure 3.2). By 
24 hours, the mean VEGF mRNA levels in the hypoxia-treated cells were still higher 
than that of the normoxic control (1.9 times the control levels) sampled at the same 
time point, though the difference between the two was not statistically significant 
i' 
(T>0.05). 
When cobalt chloride was studied for its time-dependent effect in inducing 
VEGF mRNA expression in TM3 cells, the response time of the cells appeared to 
differ from that of hypoxic treatment. The onset of an increase in VEGF mRNA 
levels was not evident until 3 hours after treatment and it plateaued at a higher level of 
about 5-6 fold above the control at 12-24 hours ^Figure 3.3). 
The concentration of cobalt chloride used in the above study appeared to 
produce the maximum changes in VEGF expression in TM3 cells. Following 6 hours 
of treatment, little changes in VEGF mRNA levels were observed under the effect of 
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Figure 3.1 Hypoxic i n d u c t i o n of VEGF mRNA expression in TM3 cells. 
TM3 cells were cultured under normoxic (5% CO2 in air with 21% O2 and 74% 
N2, Control) or hypoxic (1% O:，5% CO2, 94% N2) condition for 6 hours. Cobalt 
chloride (300 pM) treatment was tested under normoxic condition to determine 
whether it mimics the effect of hypoxia. (A) A representative Northern blot，and 
(B) the corresponding densitometric quantification of VEGF mRNA signal 
intensity after correcting for loading differences based on P-actin，and 
normalized against the control which was arbitrarily given a value of one 
(indicated by the dotted line). 
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Figure 3.2 Time course of induced increase in VEGF mRNA expression in 
T M 3 cells by hypoxic treatment. TM3 cells were cultured under normoxic (-) 
or hypoxic (+) condition for various duration ranging from 1 to 24 hours. (A) A 
representative Northern blot, and (B) combined data of densitometric 
quantification of VEGF mRNA levels. Each bar represents mean±SE (n=5) of 
the VEGF mRNA signal intensity after correcting for loading differences based 
on p-actin and expressed relative to the corresponding time control which was 
arbitrarily given a value of one (as indicated by the dotted line). 
*P<0.05 when compared with the corresponding normoxic control at the same 
time point using one-way ANOVA followed by Dunnett's test. 
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Figure 3.3 Time course of induced increase in VEGF mRNA levels in TM3 
cells by CoClj treatment. TM3 cells were cultured in the absence (control) or 
presence of300 [xM C0Cl2 for various duration ranging from 1 to 24 hours. (A) A 
representative Northem blot, and (B) combined data (mean+SE, n=5) of 
densitometric quantification of VEGF mRNA levels after correction and 
normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
using one-way ANOVA followed by Dunnett's test. 
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10 and 30 \^M C0Cl2. However at 100 ^iM concentration，there was a significant 
’ stimulation QP<0.05) of VEGF mRNA expression which was followed later by the 
maximum changes that occurred with 300 and 600 ^iM C0Cl2, achieving a 5.0-5.7 
times increase above the control OFigure 3.4). 
The above responses seen in TM3 Leydig cells could similarly be reproduced 
in TM4 Sertoli cells, though the pattern of changes appeared to differ. In a 
representative study, hypoxia was shown to induce a 3.6-fold increase in VEGF 
mRNA levels in TM4 cells at 12 hour after treatment (Figure 3.5), but again the effect 
failed to be maintained ^"igures 3.2 and 3.5)，and by 24 hours, VEGF mRNA 
expression dropped to a level which was 1.6 times the control. Cobalt chloride 
induced a rise in VEGF mRNA levels in TM4 cells, possibly also by mimicking the 
effect of hypoxia. In a single experiment, 300 ^iM C0Cl2 was seen to cause a 
transient increase in VEGF mRNA expression which peaked at 2.3-fold above the 
control after 6 hours, before falling back to levels slightly below the control at 24 
hours (Figure 3.6) 
'i 
.^ 1 
3.2 Effect of spermatic cord torsion on VEGF expression in adult rat testes 
In order to correlate the in vitro findings of a hypoxic induction of VEGF 
expression in Leydig cells and Sertoli cells to an in vivo situation, the ischaemic 
condition produced by spermatic cord torsion was being examined in adult rats. In 
animals that had spermatic cord torsion surgically induced for 6 hours, the levels of 
VEGF mRNA in the testicular tissues were significantly elevated above the sham-
operated control by 1.3-fold (Figure 3.7). 
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Figure 3.4 Concentration-dependent effect of C0CI2 in inducing the 
expression of VEGF mRNA in TM3 cells. TM3 cells were cultured in the 
absence (control) or presence of different concentrations of C0Cl2 for 6 hours. 
(A) A representative Northern blot, and (B) combined data (mean+SE, n=4) of 
densitometric quantification of VEGF mRNA levels after correction and 
normalization. 




！&^  “ 1 "^ 28S 
= 叫 帽 _ _ 就 
胃 ^ - ^ ― 18S 
P-actin 今 | _ 暴 _ _ _ _ _ _ _ _ _ 
Hypoxia _ + - + _ + • + _ + “ 
Time (hours) ~ J 3 “ 6 12 24 
Figure (B) 









> �'•� nn � 
t^ 
^ f； 
^ 1 �~~~r=n~"： ； ； ： 〜 
； ； ； • .fl 
；：.••：•：•：•：•：•；•； •.、,.•••••..*..，，. ：.:•:•:.,•:•:.•： ：.,,v.*..v.v..: 
0 4 ' " ^ ^ = ^ ~ ~ ^ “ ^ ~ ^ " “ ^ ” ^ " “ ^ ~ ~ ^ - ^ ~ ~ L ^ . ^ 
0 1 3 6 12 24 
Time Course O o^urs) 
Figure 3.5 Time course of induced increase in VEGF mRNA levels in TM4 
cells by hypoxic treatment TM4 cells were cultured under normoxic (-) or 
hypoxic (+) condition for various duration ranging from 1 to 24 hours. (A) A 
representative Northern blot, and QB) the corresponding densitometric 




^ < ~ " 28S 
^ u h ~ ^ _ _ • • _ n _ _ 爾 : _ _ 
iZkt^ — … W 看 • 1 - ^ 18S 
p-actin _ • _ _ 譽 t # m _ • m m m 
coci2(300MM) - + - + - + - + - + -




^ 2.5 -^ 
< —— 
§ 2.0 - rn : 
s Ui 
0 1 5 -
w i.J ； 、 ； > rn ^ i 
•5 1.0 r - i - : ：^*^*****^： 
^ 'i 
fVj •， 
0 . 5 _ 丨 丨 ： _ 
丨丨丨 丨丨_ll 
0.0 \ -^^ ~^ --‘ ~^'•^^ • ~^'^ •^•^^ ~~^ "-‘ ~^^ ~^~ 
0 1 3 6 12 24 
Time Course (hours) 
Figure 3.6 Time course of induced increase in VEGF mRNA levels in TM4 
cells by CoCl j treatment. TM4 cells were cultured in the absence (control) or 
presence of300 ^iM C0Cl2 for various duration ranging from 1 to 24 hours. (A) 
A representative Northern blot, and ¢ ) the corresponding densitometric 
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Figure 3.7 Effect ofspermatic cord torsion on VEGF mRNA levels in the rat 
testes. Animals in the treatment group had both testes subjected to 720 degree 
spermatic cord torsion while those in the control group received the sham-
operation. They were studied 6 hours after treatment. (A) A representative 
Northern blot, and (B) combined data (mean±SE，3 animals/group) of 
densitomeric quantification of VEGF mRNA levels after correction and 
normalization. 
*P<0.05 when compared with the control using one-way ANOVA followed by 
Dunnett's test. 
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3.3 Antagonism of hypoxic induction of VEGF expression in T M 3 cells by 
nitr ic oxide 
In view of the reciprocal interaction between VEGF and NO (as reviewed in 
the Introduction), the effects of two NO donors and a NO synthase inhibitor on 
VEGF mRNA expression in TM3 cells were being examined under both normoxic and 
hypoxic conditions. Under the basal condition when TM3 cells were cultured under a 一 
normoxic atmosphere，neither the NO donors (SNP and SNAP) nor the NOS inhibitor 
(L-NAME) being tested had any significant effect on the VEGF expression OFigure 
3.8). However, under the hypoxic condition when VEGF mRNA levels in TM3 cells 
were already stimulated by about 2.5-fold, a 6-hour treatment with either 100 \jM 
SNP or 500 ^iM SNAP produced a 43% and 23% inhibition, respectively, when 
compared with the hypoxic treatment alone. In the case of SNP (but not SNAP), the 
inhibition was statistically significant ^^<0.05). Despite the effects seen with the NO 
donors, L -NAME - a NOS inhibitor, was without any significant effect on VEGF 
mRNA levels in TM3 cells both under normoxic and hypoxic conditions. These data 
. . f| 
would tend to suggest that TM3 cells are not endogenously producing NO or their ， 
production rate is extremely low even under the hypoxic condition. 
3.4 Effect of cadmium on VEGF expression in TM3 and TM4 cells 
Similar to cobalt, cadmium is a transition metal and it exists as a divalent ion in 
CdCl2. In both TM3 Leydig cells and TM4 Sertoli cells, exposure to 30 ^iM CdCI2 
produced a significant peak of stimulation (P<0.05) of VEGF expression at 6 hours 
after treatment (Figures 3.9 and 3.11). The response ofTM3 cells was much greater 
than that o f T M 4 cells, and comparing the peak changes, it was a 3.9-fold increase 
versus a 0.5-fold increase above the control. The upregulation of VEGF expression 
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Figure 3.8 Effects of N 0 donors and NOS inhibitors on the hypoxic 
induction of VEGF mRNA expression in TM3 cells. TM3 cells grown under 
normoxic (5% 0 ¾ in air with 21% 仏 and 74% N�）or hypoxic (1% O �， 5 % CO】， 
94% N j ) condition were exposed to NO donors (100 ^iM sodium nitroprusside, 
SNP or 500 i j M S-Nitroso-N-Acetylpenicillamine, SNAP), a NOS inhibitor (1 
m M L-NAME) and its inactive analogue (1 mM D-NAME) for 6 hours. (A) A 
representative Northern blot, and (B) combined data (mean+SE, n=6) of 
densitometric quantification of VEGF mRNA levels after correction and 
normalization. 
*P<0.05, for comparison versus the normoxic control using one-way ANOVA 
followed by Dunnett's test. ,, 
卞 P<0.05, significantly different from the hypoxic treatment alone ("Hypoxia") 
based on multiple companson using one-way ANOVA followed by Student-
Newman-Keuls test. 67 
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Figure 3.9 Changes of VEGF mRNA levels in TM3 cells wi th time of 
cadmium chloride (CdCl^) treatment. TM3 cells were cultured in the absence 
(control) or presence of30 ^ M CdCl^ for various duration ranging from 1 to 24 
hours (A) A representative Northem blot, and (B) combined data (mean+SE, 
n=4) of densitometric quantification ofVEGF mRNA levels after correction and 
normalization. 
*p<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
ANOVA followed by Dunnett's test. 
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by cadmium could not be maintained in both cell types. In TM3 cells, a significant 
increase 0P<O.O5) in VEGF mRNA levels was observed between 3 and 12 hours after 
treatment, but by 24 hours, it had fallen back to the basal control value (Figure 3.9). 
In TM4 cells, VEGF expression showed a dramatic change between 12 and 24 hours 
oftreatment. At 12 hours, VEGF mRNA levels were already back to basal after the 
transient increase at 6 hours. However in the next 12 hours, they showed a 
tremendous fall to reach only 26% of the levels found in the control, probably as a 
result of a direct toxic effect of Cd to this cell type. This would be in line with the 
. observation of more cells becoming detached from the bottom of the culture dish after 
this period of the treatment (24 hours with 30 ^iM CdCb)，and a reversal of the dose 
response relationship when TM4 cells were exposed to a higher concentration of 
CdCl2 (i.e. 100 ^iM for 6 hours) (Figure 3.12). 
In TM3 cells, a significant stimulation 0P<O.O5) of VEGF expression was 
observed 6 hours after treatment with 10 ^iM CdCl2 and the maximum response was 
seen with 30 pM CdCl2 (Figure 3.10). With a higher dose of 100 ^ M CdCl2, a slight : 
"i' 
-1 
fall in mRNA levels was recorded in place of a further increase even though the mean 
value was still significantly higher (T<0.05) than the corresponding time control by 
2.2-fold. As for the TM4 cells, the stimulation ofVEGF expression by cadmium was 
smaller and significant increases (P<0.05) were observed with 10 and 30 ^iM CdCl2 
OFigure 3.12). With a higher concentration of 100 ^iM C0Cl2, the trend completely 
reversed and the mean VEGF mRNA levels (arbitrary value of 1.007) became 
identical to those of the control. 
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Figure 3.11 Changes o fVEGF mRNA levels in TM4 cells with time o fCdCl j 
treatment. TM4 cells were cultured in the absence (control) or presence of 30 
|oM CdCl2 for various duration ranging from 1 to 24 hours. (A) A representative 
Northern blot, and OB) combined data (mean±SE，n=3) of densitometric 
quantification ofVEGF mRNA levels after correction and normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
ANOVA followed by Dunnett's test. 
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Figure 3.12 Concentration-dependent effect of CdCl】 on VEGF mRNA 
levels in T M 4 cells. TM4 cells were cultured in the absence (control) or 
presence of different concentrations of CdCl2 for 6 hours. (A) A representative 
Northern blot, and (B) combined data (mean+SE, n=4) of densitometric 
quantification ofVEGF mRNA levels after correction and normalization. 
*P<0.05 when compared with the control using one-way ANOVA followed by 
Dunnett's test. 
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3.5 Effect of dexamethasone on Cd-induced increase in VEGF expression in 
T M 3 cells 
Dexamethasone (1 piM) or its vehicle alone (0.005% ethanol) had no 
.s igni f icant effect on the basal expression of VEGF in TM3 cells (Figure 3.13). 
However, similar to the effect of nitric oxide, dexamethasone (but not its vehicle) 
caused a significant inhibition (24%) 0P<O.O5) of"the stimulated increase in VEGF 
mRNA level which in this case, was induced by a 6-hour treatment with 30 ^iM 
CdCl2. 
3.6 Effect of cadmium treatment on VEGF expression in the adult rat testes 
In order to correlate the VEGF response in testicular cells following in vitro 
exposure to cadmium to the possible involvement of this peptide in mediating the 
cadmium-induced vascular permeability increase in the testis, a number of in vivo 
studies were performed in the rats examining the effect of cadmium in isolation or in 
combination with other forms of treatment. In rats that had received a single 
intraperitoneal injection of CdCl2 (6 mg/kg body weight), significant stimulation 
(P<0.05) o fVEGF mRNA levels in testicular tissues was observed at 6 and 12 hours 
after treatment (Figure 3.14). In fact, at these two time point, the mean VEGF 
mRNA levels in the testes were almost identical and represented a 1.4- and a 1.3-fold 
increase above the control, respectively. Preliminary studies also indicated that with 
this route and dose 0fCdCl2 injection, a more consistent response could be observed. 
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Figure 3.13 Effect of dexamethasone on CdClj-induced increase in TM3 
cells. Dexamethasone (1 [ M ) or the vehicle [ethanol (EtOH), final concentration 
of 0.005% in culture] immediately prior to the treatment with or without CdCl2 
(30 nM) for a 6 hours. (A) A representative Northern blot，and OB) combined 
data (mean+SE, n=4) of densitometric quantification ofVEGF mRNA levels after 
correction and normalization. 
*P<0.05 for comparison versus the “Control” (with no treatment) using one-way 
ANOVA followed by Dunnett's test. 
tP<0.05 significantly different from "CdCl2 + EtOH" treatment group based on 
multiple comparison using one-way ANOVA followed by Student-Newman-
Keuls test. 
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Figure 3.14 Effect of CdClj on VEGF mRNA levels in adult rat testes. Rats 
were given a single intraperitoneal (i.p.) injection ofCdCl】(6 mg/kg bw) or the 
vehicle (control) and studied at 6 and 12 hours after treatment. (A) A 
representative Northern blot, and OB) combined data (mean+SE, 3 animals/group) 
of densitometric quantification of VEGF mRNA levels in the testes after 
correcting for loading difference based on P-actin and normalized against the 
control which was arbitrarily given a value ofone. 
*P<0.05 when compared with the control using one-way ANOVA followed by 
Dunnett's test. 
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3.7 Effect of Leydig cell depletion on basal and Cd-induced expression of 
VEGF in adult rat testes 
Following the removal ofLeydig cells by ethane dimethane sulphonate (EDS) 
treatment, VEGF mRNA levels in the testis was reduced by 39% when compared 
with the intact control group without receiving any treatment ^^igure 3.15). I t was 
not clear whether this was due to the removal of the Leydig cells since the injection of_ 
the vehicle for EDS (i.e. DMSO treatment) produced a similar decrease (32%) in 
VEGF mRNA levels in the testis. Leydig cell depletion did not abolish the cadmium-
induced increase in VEGF expression in the testis at 12 hours after treatment 
OEDS+CdCl2), though when compared with the vehicle injected group with intact 
testes 03MSO+CdCl2), it showed a 29% decrease ^"igure 3.15). 
3.8 Effect of dexamethasone on basal and Cd-induced expression of VEGF in 
adult rat testes 
Unlike the results obtained in vitro where the basal expression of VEGF in 
TM3 cells was not affected by a 6-hour treatment with dexamethasone, prior daily 
injection of adult rats with dexamethasone (1 mgy :^g bw) for 4 days produced a 
significant inhibition 0P<O.O5) of VEGF expression in the testes ^Figure 3.16). The 
inhibitory effect from repeated injections of dexamethasone in vivo was so profound 
that even the cadmium-stimulated increase in VEGF expression after a 6-hour 
treatment was completely abolished. Part of these changes could be reflected in the 
loss of VEGF immunoreactivity, particularly from the Leydig cells as revealed by 
immunostaining ^"igure 3.18). 
In parallel with the loss of VEGF response to cadmium in the testes of the 
dexamethasone-treated animals, there was a marked reduction in the ability of 
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Figure 3.15 Effect of CdClj on VEGF mRNA levels in intact and Leydig cell 
-depleted adult rat testes. Adult rats were given a single intraperitoneal (i.p.) 
injection of ethane dimethyl sulfonate O^DS，75 mgy^g bw) OLeydig cell -
depleted group) or the vehicle (1:3 DMSO:water, v/v) (DMSO - intact group) 3 
days prior to receiving a single i.p. injection of CdCl2 (6 mg/kg bw) or the vehicle 
(saline) and studied 12 hours later. (A) A representative Northern blot, and (B) 
combined data (mean+SE, 3 animals/group) of densitometric quantification of 
VEGF mRNA levels in the testes after correction and normalization. 
*P<0.05 for comparison versus the "Control" group (with no treatment) using 
one-way ANOVA followed by Dunnett's test. 
fP<0.05 significantly different from “DMSO+CdCy’ treatment group based on 
multiple comparison using one-way ANOVA followed by Student-Newman-
Keuls test. 77 
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Figure 3.16 Effect of dexamethasone on CdCl2-induced increase in VEGF 
mRNA levels in adult rat testes. Adult rats were given a single subcutanous 
injection ofdexamethasone (1 mgyTcg bw) or the vehicle (com oil) on each ofthe 
four consecutive days. One hour after the last injection, CdCl2 (6 mgy^g bw) or 
the vehicle (saline) was injected intraperiotoneally to these animals and studied 6 
hour later. (A) A representative Northern blot，and (B) combined data (mean±SE, 
4-5 animals/group) of densitometric quantification of VEGF mRNA levels in the 
testes after correction and normalization. 
*P<0.05, for comparison versus the “Control，，group (vehicle-injected) using one-
way ANOVA followed by Dunnett's test. 
tP<0.05, significantly different from "CdCl2" treatment group based on multiple 
comparison using one-way ANOVA followed by Student-Newman-Keuls test. 
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cadmium to induce vascular permeability increase in the testicular vasculature 
’ OFigures 3.17 and 3.18). Instead of acquiring a highly haemorrhagic appearance at 6 
hours after CdCl2 treatment [Figure 3.17(A)], testes of dexamethasone pre-treated 
animals were protected from such vascular changes P^igure 3.170B)]. The leakage of 
plasma protein was less evident and there was little disruption of the spermatogenic 
process in the seminiferous tubules (Figure 3.18). 一 
3.9 Effects of hCG, forskolin and phorbol ester on VEGF expression in TM3 
and TM4 cells 
To test whether VEGF expression in the testis could be hormonally regulated, 
and thus it could be responsible for mediating the vascular effect of hCG in inducing 
permeability increase and endothelial proliferation in the testicular vasculature, VEGF 
mRNA levels were determined in the testes of adult rats after they received a single 
subcutaneous injection of 100 EJ hCG. Out of the original expectation, VEGF 
mRNA levels in the testes remained unchanged 24 hours after the animals were 
injected with hCG (Figure 3.19). The experiment had been repeated a few times and 
gave similar results. Similar results were obtained in vitro when TM3 Leydig cells 
were exposed to 1 EJ/ml hCG ^"igure 3.20) for a duration ranging from 1 to 24 
hours. 
However, when TM3 cells were treated with 1 ^ M forskolin (Figure 3.21) and 
1 mM 8-(4-chlorophenylthiol)-cAMP (an analog ofcAMP) (Figure 3.23)，a 1.8- and a 
1.7-fold increase in the VEGF mRNA levels were noted respectively, within the first 3 
hours after treatment. The effect of forskolin peaked after the first hour and then 
gradually declined until at 3 hours, the difference in VEGF mRNA levels between the 
treatment group and the controls (untreated or exposed to the vehicle alone) was no 
79 
-_ 1 1 
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Figure 3.17 Appearance of the testis from (A) an adult rat that received CdCl2 
injection (6 mgA:g bw) 6 hours earlier, OB) an adult rat that received daily 
injection of dexamethasone (1 mg/kg bw) for 4 days prior to being injected with 
CdCl2 (6 mg/kg bw) and examined 6 hours later, (C) an adult rat that received 
daily injection of dexamethasone for 4 days, and pD) a control adult rat. Note the 
haemorrhagic appearance of the testis from the CdClj-injected rat in (A), and the 
difference produced by prior dexamethasone treatment as shown in (B). 
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Figure 3.18 Immunohistochemical staining for VEGF in the testis of (A) a 
control adult rat，(B) an adult rat that received CdCl】 injection (6 mg/kg bw) 6 
hours earlier, (C) an adult rat that received daily injection of dexamethasone for 4 
days, and ^D) an adult rat that was treated with dexamethasone [as in (C)] prior to 
receiving CdCl2 injection (6 mgy1cg bw) and examined 6 hours later. 
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Figure 3.19 Effect of human chorionic gonadotrophin (hCG) on VEGF 
mRNA levels in adult rat testes. Adult rats were given a single subcutaneous 
injection of 100 KJ hCG or saline (control) and studied at 24 hours post-injection. 
(A) A representative Northern blot, and fB) combined data (mean+SE, n=2) of 
densitometric quantification of VEGF mRNA levels in the testes after correction 
and normalization. There was no significant difference between the control and 
the hCG-injected group. 
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Figure 3.20 Changes of VEGF mRNA levels in TM3 cells wi th time of 
treatment wi th hCG. TM3 cells were cultured in the absence (control) or 
presence of 1 KJ/ml hCG for various duration ranging from 1 to 24 hours. (A) A 
representative Northern blot, and (B) combined data (mean+SE, n=5) of 
densitometric quantification of VEGF mRNA levels after correction and 
normalization. There was no significant difference between the treatment group 
and the corresponding control at each time point. 
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Figure 3.21 Changes of VEGF mRNA levels in TM3 cells wi th time of 
treatment with forskolin. TM3 cells were cultured in the absence (control,"-") 
or presence of 1 ^iM forskolin (“+”）or its vehicle O^MSO, “# ” final 
concentration of 0.005% in culture) for various duration ranging from 1 to 3 
hours. (A) A representative Northern blot, and (B) combined data (mean+SE, 
n=3) of densitometric quantification of VEGF mRNA levels after correction and 
normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
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Figure 3.22 Concentration-dependent effect of forskolin on VEGF mRNA 
levels in TM3 cells. TM3 cells were cultured in absence (control), or presence of 
different concentrations of forskolin or its vehicle (0.05% DMSO) for 1 hour. 
(A) A representative Northem blot, and (B) combined data (mean+SE, n=3) of 
densitometric quantification of VEGF mRNA levels after correction and 
normalization. 




： ^ 1 - < — 28S 
v E G F _ ^ _ m _ m _ _ _ 
3.7kb 冒 署 W \ W 冒 胃 霄 ’ 
^ ^ , . ^ ^ _ j ^ ^ _ 18S 
8-(4-chlorophenylthio) _ + _ + _ + _ 
-cAMP sodium 
Time (hours) 0 1 2 3 
Figure (B) 
3.0 1 
一 2 . 5 -
0 
JJ 
< 2.0 - 、 
2 
c :_!j 
Uu 1 N _ '、」 
0 1.) < 
UJ � i 
> V 
1 1.0 ——n——~—— 
_ 2 、 ^ ^ , . � 
0.5 - : 
0.0 \ I 丨 I r~"i .~~L_ 
Control 1 2 3 
Time (hours) 
Figure 3.23 Changes of VEGF mRNA levels in TM3 cells with time of 
treatment with a cAMP analogue - 8-(4-chIorophenylthio)-cAMP sodium. 
TM3 cells were cultured in the absence (control), or presence of 1 mM 8-(4-
chlorophenylthio)-cAMP sodium for various duration ranging from 1 to 3 hours. 
(A) A representative Northern blot, and (B) the corresponding densitometnc 
quantification of VEGF rnRNA signal intersity after correction and 
normalization. 
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longer statistically significant CP>0.05) (Figure 3.21). In TM3 cells, the effect of 
» 
forskolin on VEGF expression was also shown to be concentration-dependent. When 
VEGF mRNA levels were determined after the first hour of exposure to 0.03-10 p M 
forskolin, they showed dose-related increase reaching significantly higher values 
(P<0.05) at 1 and 10 [sM concentration of forskolin OFigure 3.22). 
Similar to TM3 cells, VEGF expression in TM4 cells was also upregulated by 
forskolin (1 pM). During a three-hour treatment period, a transient but significant 
stimulation (P<0.05) ofVEGF mRNA levels was observed at 2 hours, reaching about 
- a 100% increase above the control fFigure 3.24). Nevertheless, preliminary studies 
also revealed that TM4 cells failed to respond to the hormonal stimulation by FSH 
with an increase in VEGF expression (data not shown). 
On an equimolar basis (1 ^dVl), PMA was more potent than forskolin in 
stimulating VEGF expression in TM3 (Figures 3.21 and 3.25) and TM4 (Figures 3.24 
and 3.27) cells. TM3 cells responded to 1 ^iM PMA with significant upregulation 
(P<0.05) ofVEGF mRNA levels at 2 and 3 hours after treatment, reaching a 4.7- and 
a 3.9-fold increase above the control, respectively (Figure 3.25). The PMA (1 ^iM) 
effect on TM4 cells followed a similar time course. VEGF mRNA levels were 
significant increased (P<0.05) to 3.4-fold above the control at 2 and 3 hours after 
PMA treatment. (Figure 3.27). The concentration-dependent effect of PMA on 
VEGF expression was demonstrated in TM3 cells over a range of 0.01-3 p,M PMA 
after a 2-hour treatment (Figure 3.26). Statistical analyses revealed that the 
stimulation was significant at 0.3-3 p_M PMA, with a 3-4 folds increase in VEGF 
mRNA levels above the control. In addition, the PMA effect on TM3 cells appeared 
to plateau off at around 1-3 ^iM concentration. 
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Figure 3.24 Changes of VEGF mRNA levels in TM4 cells with time of 
treatment with forskolin. TM4 cells were cultured in the absence (control，“-，’） 
or presence of 1 p M forskolin (“+”）or its vehicle (0.005% DMSO) for various 
duration ranging from 1 to 3 hours. (A) A representative Northern blot, and (B) 
combined data (mean+SE, n=3) of densitometric quantification of VEGF mRNA 
levels after correction and normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
ANOVA followed by Dunnett's test. 
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Figure 3.25 Changes of VEGF mRNA levels in TM3 cells wi th time of 
treatment with phorbol-12-myristate-13-acetate (PMA). TM3 cells were 
cultured in the absence (control, “-”）or presence of 1 [ iM PMA (“+”）or its 
vehicle DMSO (0.05% DMSO) for various duration ranging from 1 to 3 hours. 
(A) A representative Northern blot, and (B) combined data (mean+SE, n=4) of 
densitometric quantification of VEGF mRNA levels after correction and 
normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
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Figure 3.26 Concentration-dependent effect of PMA on VEGF mRNA levels 
in TM3 cells. TM3 cells were cultured in absence (control), or presence of 
different concentrations o fPMA or its vehicle (0.15% DMSO) for 2 hour. (A) A 
representative Northern blot, and (B) combined data (mean±SE，n=3) of 
densitometric quantification of VEGF mRNA levels after correction and 
normalization. 
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Figure 3.27 Changes of VEGF mRNA levels in TM4 cells wi th time of 
treatment wi th PMA. TM4 cells were cultured in the absence (control, “-”）or 
presence of 1 ^ M PMA (“+”）or its vehicle (0.05% DMSO, “#”）for various 
duration ranging from 1 to 3 hours. (A) A representative Northern blot, and (B) 
combined data (mean+SE, n=4) of densitometric quantification of VEGF mRNA 
levels after correction and normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
ANOVA followed by Dunnett's test. 
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3.10 Effect of hCG on VEGF expression in M L T C - 1 cells 
Unlike TM3 Leydig cells, MLTC-1 cells derived from Leydig cell tumour are 
known to retain their L H responsiveness even after repeated passages in culture. 
VEGF expression in these cells was shown to be significantly upregulated (P<0.05) 
during a 1-6 hours treatment period by 1 RJ/mi hCG (Figure 3.28). The peak 
increase occurred at 2 hours post-hCG treatment when it reached 4.2 times the 
control levels. When the dose-dependent effect of hCG on MLTC-1 cells was 
examined at 2 hours after treatment, significant (P<0.05) but more or less uniform 
. increases in VEGF mRNA levels were observed with 0.01 to 3 EJ/ml of hCG (Figure 
3.29). These data would tend to suggest that the maximum effect o fhCG might have 
already been attained at a concentration below 0.01 KJ/ml. 
3.11 Effects of lL- la，EL-ip, IL-6, TNF-a and TNF-P on VEGF expression in 
TM3 cells 
In view of the possible involvement of VEGF in Leydig cell-testicular 
macrophage interaction, the control of VEGF expression in Leydig cells was 
examined under the effects of macrophage-derived cytokines (and growth factors). 
Over a 48-hour period, the three interleukins that were being tested (EL-la, EL-ip 
and JL-6) at 10 ng/ml were shown to be devoid of any effects on VEGF expression in 
TM3 cells (Figures 3.30，3.31 and 3.32). On the other hand, both TNF-a (Figure 
3.33) and TNF-p (Figure 3.35) were able to induce a small increase ofVEGF mRNA 
levels in TM3 cells after a 6-hour incubation at 10 ng/ml. However, only the TNF-a 
effect was statistically significant (P<0.05) and represented a 75% increase (versus a 
51% increase for TNF-P) over the control. At other time points, the changes in 
VEGF mRNA levels appeared to be less consistent and did not follow a regular 
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Figure 3.28 Changes of VEGF mRNA levels in MLTC-1 cells wi th time of 
treatment with hCG. MLTC-1 cells were cultured in the absence (control) or 
presence of 1 KJ/ml hCG for various duration ranging from 1 to 6 hours. (A) A 
representative Northern blot, and (B) combined data (mean±SE，n=4) of 
densitometric quantification of VEGF mRNA levels after correction and 
normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
ANOVA followed by Dunnett's test. 
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Figure 3.29 Concentration-dependent effect of hCG on VEGF mRNA levels 
in M L T C - 1 cells. MLTC-1 cells were cultured in absence (control), or presence 
of different concentrations of hCG for 2 hour. (A) A representative Northem 
blot, and (B) combined data (mean+SE, n=3) of densitometric quantification of 
VEGF mRNA levels after correction and normalization. 
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Figure 3.30 Changes of VEGF mRNA levels in TM3 cells wi th time of 
treatment with interleukin-la QDL-loc). TM3 cells were cultured in the absence 
(control) or presence of recombinant murine EL-loc (10 ngAnl) for various 
duration ranging from 1 to 48 hours. (A) A representative Northern blot，and ¢8) 
combined data (mean+SE, n=3) of densitometric quantification of VEGF mRNA 
levels after correction and normalization. No significant changes in VEGF 




= 一 _ _ 警 賺 ^ ^ » ^ 二 : 
p ‘ n — m m m m m r n m m m m m m W 
n . - l p ( lOng /m l ) - Hh - + - + - + - + - + -
Time (hours) ^ " " " i ~ " 3 6 12 24 48 
Figure (B) 
1.50 - __ 
>^^  :.:•>:.:-:•:.:.:•: 
i 1.25 - 门 T : T 
i i J L r : t u _ i _ n 
S 1.00 .,___  • ^ ^—•秦― F ^ ~ ―；— 一丨一‘^ -
S 、 、 ： 、- ； 、 \ . 一 ； 、 
b 、、、、 \ 
S 0-75 - 、 i ； L i 
J> 、、、 、 i 
I 0.50 • 、 i 
rB 、： <p > : e2 、； 
0 . 2 5 - 、 、丨 
:v.w...v.,.; .:•，.:•:•:,•:.： ：•:.•:.•:•:•:•:. .....Y.v.....x •:.:•:•:•:•:•:.:•:: ••••••.•••••.••...: 
0.00 4 ^^~~^=^~~^‘^~~^-^~^^^~^^^~~^-^~‘ 
Control 1 3 6 12 24 48 
Time Qiours) 
Figure 3.31 Changes of VEGF mRNA levels in TM3 cells with time of 
treatment wi th interleukin-lp 0 [L- lp). TM3 cells were cultured in the absence 
(control) or presence of recombinant murine EL-ip (10 ng/ml) for various 
duration ranging from 1 to 48 hours. (A) A representative Northern blot, and (B) 
combined data (mean+SE, n=3) of densitometric quantification of VEGF mRNA 
levels after correction and normalization. No significant changes in VEGF 
mRNA levels could be detected at any of the time points being examined. 
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Figure 3.32 Changes of VEGF mRNA levels in TM3 cells wi th time of 
treatment with interleukin-6 ODL-6). TM3 cells were cultured in the absence 
(control) or presence of recombinant murine JL-6 (10 ngy^ml) for various duration 
ranging from 6 to 48 hours. (A) A representative Northern blot，and (B) 
combined data (mean+SE, n=2) of densitometric quantification o fVEGF mRNA 
levels after correction and normalization. No significant changes in VEGF 
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Figure 3.33 Changes of VEGF mRNA levels in TM3 cells wi th time of 
treatment wi th tumour necrosis factor-a (TNF-a). TM3 cells were cultured in 
the absence (control) or presence of recombinant murine TNF-a (10 ng/ml) for 
various duration ranging from 1 to 24 hours. (A) A representative Northern blot, 
and (B) combined data (mean+SE, n=3) of densitometric quantification ofVEGF 
mRNA levels after correction and normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
ANOVA followed by Dunnett's test. 
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Figure 3.34 Concentration-dependent effect of TNF-a on VEGF mRNA 
levels in TM3 cells. TM3 cells were cultured in the absence (control) or 
presence of different concentrations ofTNF-a for 6 hours. (A) A representative 
Northern blot, and ¢3) the corresponding densitomertric quantification of VEGF 
mRNA signal intensity after correction and normalization. 
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Figure 3.35 Changes of VEGF mRNA levels in TM3 cells wi th time of 
treatment wi th tumour necrosis factor-P (TNF-P). TM3 cells were cultured in 
the absence (control) or presence of recombinant murine TNF-P (10 ngAnl) for 
various duration ranging from 1 to 24 hours. (A) A representative Northern blot, 
and OB) combined data (mean+SE, n=3) of densitometric quantification of VEGF 
mRNA levels after correction and normalization. No significant changes in 
VEGF mRNA levels could be detected at any of the time points being examined. 
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Figure 3.36 Concentration-dependent effect of TNF-P on VEGF mRNA 
levels in TM3 cells. TM3 cells were cultured in the absence (control) or 
presence of different concentrations of TNF-P for 6 hours. (A) A representative 
Northern blot, and ^B) the corresponding densitometric quantification of VEGF 
mRNA signal intensity after correction and normalization. 
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pattern. Nonetheless, the effects o fTNF-a (Figure 3.34) and TNF-p (Figure 3.36) on 
VEGF expression in TM3 cells were shown to be concentration-dependent over a 
range of 0.3 to 30 ng/ml when examined at 6 hours after treatment. 
3.12 Effects of bFGF and TGF-p i on VEGF expression in TM3 cells 
— bFGF ^t 10 ngAnl produced a significant stimulation (P<0.05) of VEGF 
mRNA expression in TM3 cells after 24 hours, giving a 1.2-fold increase above the 
control ^'igure 3.37). The effect of bFGF was also shown to be concentration-
. dependent. Afler a 24 hour incubation, significant increases (P<0.05) of VEGF 
mRNA levels in TM3 cells were observed under the effect of 10 and 30 ng/ml of 
bFGF (Figure 3.38). Based on the present observations, it appeared that the bFGF 
efFect on VEGF expression in TM3 cells might have already plateaued at these 
concentrations. 
Similar to bFGF, TGF-P1 (10 ngAnl) produced a significant upregulation 
(P<0.05) ofVEGF mRNA levels in TM3 cells after 24 hours (Figure 3.39)，producing 
a 100% increase above the control. In a representative experiment, TGF-pl efFect 
was also shown to be concentration-dependent, giving a near maximum response with 
10-30 ng/ml ofthis peptide ^"igure 3.40). 
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Figure 3.37 Changes of VEGF mRNA levels in TM3 cells with time of 
treatment with basic fibroblast growth factor (bFGF). TM3 cells were 
cultured in the absence (control) or presence of recombinant human bFGF (10 
ng/ml) for various duration ranging from 6 to 48 hours. (A) A representative 
Northem blot, and (B) combined data (mean+SE, n=4) of densitometric 
quantification ofVEGF mRNA levels after correction and normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
ANOVA followed by Dunnett's test. 
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Figure 3.38 Concentration-dependent effect of bFGF on VEGF mRNA 
levels in TM3 cells. TM3 cells were cultured in the absence (control) or 
presence ofdifferent concentrations ofbFGF for 24 hours. (A) A representative 
Northern blot，and (B) combined data (mean±SE, n=4) of densitometnc 
quantification k v E G F mRNA levels after correction and normalization. 
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Figure 3.39 Changes of VEGF mRNA levels in TM3 cells with time of 
treatment with transforming growth factor>pi (TGF-pi) . TM3 cells were 
cultured in the absence (control) or presence of recombinant human TGF-P1 (10 
ng/ml) for various duration ranging from 6 to 48 hours. (A) A representative 
Northern blot, and (B) combined data (mean+SE, n=4) of densitometric 
quantification ofVEGF mRNA levels after correction and normalization. 
*P<0.05 when compared with the corresponding control at the same time point 
(arbitrarily given a value of one as indicated by the dotted line) using one-way 
ANOVA followed by Dunnett's test. 
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Figure 3.40 Concentration-dependent effect of TGF-p i on VEGF mRNA 
levels in TM3 cells. TM3 cells were cultured in the absence (control) or presence 
of different concentrations of TGF_pi for 24 hours. (A) A representative 
Northern blot, and ⑶ the corresponding densitomertric quantification of VEGF 
mRNA signal intensity after correction and normalization. 
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4. 2)iscussion 
The overall aim of the present investigation was to examine the control of 
、 VEGF expression in the testes using the technique ofNorthem blot analysis. Utilizing 
in vitro cultures of testicular cell lines allows the two major cell types (i.e. Leydig 
cells and Sertoli cells) that are expressing VEGF in the testis to be studied 
independent of each other. The cell culture system also allowed the effects of the 
various test substances to be examined in isolation and at defined concentrations and 
duration of treatment. Nonetheless, every attempt was made in trying to correlate the 
in vitro findings to analogous situations that might exist in vivo within the body of the 
whole animal. 
In the present study, two mouse cell lines were chosen for the investigation 
since they are clonal cell lines that have retained many characteristics of the normal 
cells (e.g. exhibiting contact inhibition by growing in culture as a monolayer, retaining 
a normal steroidogenic capacity of producing testosterone rather than progesterone 
for the TM3 Leydig cells). TM4 cells also represent the only Sertoli cell line that is 
commercially available. Furthermore, they are derived from the same source (i.e. by 
J. Mather from testes of ICR mice) which allows comparisons to be made, i f required, 
between their responses. They exhibit a short doubling time which allowed more 
experiments to be completed within a shorter span of time. The only drawback 
however is the fact that they are derived from the mouse which makes the comparison 
against the in vivo studies done in the rat more difficult. But then, mice would not be 
an appropriate choice for the whole animal experiment since the amount o fRNA that 
could be extracted from the whole testis is small. In addition, for in vivo studies that 
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were required for the present investigation, the baseline information (e.g. hCG-
‘ induced vascular changes in the testes, effect of spermatic cord torsion) was less 
abundant in the mice when compared with the rats. ICR mice are also known to be 
. m o r e susceptible to the cadmium toxicity, the animals die of other causes before the 
testes would manifest signs of cadmium-induced vascular permeability changes 
[Fielder&Dale,1983]. — -
4.1 Upregulation o fVEGF expression in TM3 and TM4 cells by hypoxia and 
cobalt chloride 
The present data demonstrated that hypoxia induced an upregulation of VEGF 
expression in both TM3 Leydig cells and TM4 Sertoli cells. This is similar to other 
published studies which show a universal increase in VEGF gene expression in many 
cell types exposed to hypoxic treatment in vitro. These include some normal [Ladoux 
& Frelin, 1993; Brogi et al, 1994; Hlatky et al, 1994; Minchenko et al.’ 1994; Liu et 
al.，1995;Nomura et al, 1995;Pe'er et al, 1995; Shima et al, 1995] and tumor cells 
[Plate et al, 1992; Ikeda et al, 1995; Levy et al.，1995; Shweiki et al, 1995]. 
However, it was also noted that the basal VEGF mRNA expression and the 
magnitude ofinduction by hypoxia varied among the different cell types. 
In both TM3 and TM4 cells, the hypoxic induction of VEGF expression could 
be mimicked by cobalt chloride treatment. The same action due to cobalt ions has 
also been reported in the stimulation of VEGF expression in myocytes [Ladoux & 
Frelin, 1994], tumour or transformed cell lines [Gleadle et al, 1995], and whole 
animals ^:.adoux & Frelin, 1994; Sandner et al, 1997a]. The fact that Co:+ mimicks 
the effects of hypoxia on VEGF mRNA expression has been taken as a strong 
evidence in favour of the hypothesis that an oxygen sensor (as reviewed in the 
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Introduction) controls VEGF gene expression in a manner independent of the change 
‘ in energetic state ofthe cells [Goldberg & Schneider, 1994; Ladoux & Frelin，1994] 
under low oxygen tension. 
Although in the present studies, only the dose-dependent effect of cobalt 
chloride was investigated by varying its concentrations added to the culture, it is 
believed that VEGF expression could be increased in concordance with the extent"of 
hypoxia. Based on other studies, increased VEGF expression was typically first 
evident at oxygen concentrations below 10% and maximal at levels below 5% [Liu et 
_ cd., 1995]. 
Using RNA blot analysis, Goldberg & Schneider [1994] demonstrated a time-
related induction of VEGF expression in rat hepatoma cells line Hep3B exposed to 
100 ^ M C0Cl2. Significant stimulation was also observed with higher C0Cl2 
concentration of 200 and 300 ^ M in rat glioma C6 cell line after 24 hours incubation 
[Ikeda et al” 1995]. Ladoux and Frelin [1994] demonstrated that the action of Co〗+ 
on cultured rat cardiomyocytes became apparent after 2 hours of incubation and 
reached a maximum after 4 hours. A concentration-dependent effect was 
demonstrated between 1 and 30 jig/ml. Using the same system of cultured myocytes 
from new-bom mice, Eyssen-Hemandez etal. [1996] showed a statistically significant 
action of Co^^ on VEGF mRNA expression at 230 | iM and the maximum stimulation 
was 2-fold. In the present study, the concentration of C0Cl2 required to induce an 
increase in VEGF mRNA levels in TM3 and TM4 testicular cell lines was shown to be 
slightly greater. This might reflect the different abilities of various cell types to take 
up cobalt ions or the different amounts of heme groups that are associated with the 
oxygen sensors and would be ready to interact with the Co。+ [Goldberg & Schneider, 
1994]. 
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The present data showed that the stimulatory effect of hypoxia and Co?+ on 
‘ VEGF mRNA levels in both TM3 and TM4 cells could not be maintained. Over a 24-
hour period, the VEGF mRNA levels increased, peaked at 6-12 hours and then 
declined towards the basal. So the response appeared to differ from human hepatoma 
cell lines which gave a more stable VEGF expression between 6 and 24 hours of 
C0Cl2 treatment [Goldberg & Shneider，1994]. As in hepatama cell lines, the hypoxic 
induction of VEGF expression also peaked later than TM3 and TM4 cells at 24 hours 
[Goldberg & Shneider，1994], so it remains unclear whether such differences in the 
time-related responses are due to the different cell types or different mechanisms 
operating within the cells to determine the VEGF mRNA stability. It has been shown 
in C6 rat glioma cells [Ikeda et al, 1995], human retinal epithelial cells [Shima et al” 
1995] and P12 rat pheochromocytoma cells [Levy et al, 1995; Levy et aL, 1996], 
hypoxia induces an increase in VEGF mRNA levels not only through a transcriptional 
activation of VEGF gene but also by increasing the stability of the VEGF mRNA. It 
remains to be determined how these two mechanisms may operate within the TM3 
and TM4 testicular cells to give rise to the time-related changes in the VEGF mRNA 
levels under hypoxia or following other treatments being investigated in this study. 
4.2 Effect of testicular torsion on VEGF expression in aduIt rat testes 
The present study also demonstrated that VEGF mRNA levels were increased 
in those testes that had been exposed to an ischaemic treatment caused by the surgical 
induction of spermatic cord torsion. Such an effect could be related to the in vitro 
demonstration of a hypoxic-induction of VEGF expression in both TM3 Leydig cells 
and TM4 Sertoli cells. The present findings are similar to other reported works which 
show an increase in VEGF expression in vivo associated with a variety of pathological 
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processes characterized by hypoxia-related neovascularization. For example, VEGF 
1 production is augmented during tissue ischaemia [Banai et al, 1994b; Hashimoto et 
al, 1994], wound healing [Brown et al, 1992], proliferative retinopathy [Pierce et 
al., 1995], and tumour progression [Plate et al, 1992; Shweiki et al, 1992; Brown et 
al, 1995; Hatva et al., 1995]. More recently a study in the mice has shown that 
hypoxemic hypoxia induces increased VEGF expression by 4-fold in the brain, 3-feld -
in the testis, and about 2-fold in heart, lung, kidney and liver [Marti & Risau, 1998]. 
4.3 Antagonism of hypoxic induction of VEGF expression in TM3 cells by 
nitr ic oxide 
The present study demonstrated that the hypoxia-induced increased expression 
of VEGF in TM3 cells was decreased in the presence of nitric oxide donors. This 
would be in line with earlier reports of an antagonistic effect of NO on VEGF 
production. Liu and his co-workers [1998] demonstrated that NO inhibited the 
hypoxic induction of VEGF at the transcriptional level in rat aortic smooth muscle 
cells (RASMC). RASMCs were treated with the NO donors - S-nitrosoglutathione 
(GSNO) (50-500^iM) and SNP (500|iM) for 12 hours under hypoxic or normoxic 
conditions. Results showed that NO donors dose-dependently reduced VEGF mRNA 
levels under hypoxia. In an in vivo study, Tuder et al [1995] also showed that 
hypobaric hypoxia (either acutely or chronically) increased VEGF gene expression in 
the lung tissue, whereas endotoxin time-dependently decreased it. Since endotoxin is 
a powerful activator o fNO synthesis [Kilbourn & Belloni，1990], they hypothesized 
that endotoxin decreased lung tissue VEGF gene expression via the induction of NO 
synthesis in the lung. In agreement with this hypothesis, they found that the NO 
donor SNP inhibited the hypoxia-induced upregulation of lung VEGF gene 
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expression. Moreover, inhibition of NO synthesis by L-NAME during normoxic or 
‘ hypoxic ventilation of isolated lungs increased VEGF gene expression, indicating that 
endogenously produced NO was important in this process [Hasunuma et al, 1991; 
Eddahibi et al, 1992]. Since during chronic hypoxia, endogenous NO production in 
the lung is likely to be increased [Barer et al, 1993; Amet et al, 1996] so the NO 
may serve as a regulatory signal to limit the increase in VEGF gene expression caused-
by hypoxia. 
In the present study of TM3 cells, it was not possible to demonstrate an 
inhibition of VEGF expression by NO donors (SNP or SNAP) under normoxic 
condition, or a stimulation in the presence of a NO synthase inhibitor - L-NAME. 
These findings would suggest that in TM3 Leydig cells, the basal (or constitutive) 
expression ofVEGF is not under the regulation by NO. This appears to be analogous 
to the situation in MA-10 mouse Leydig tumour cells where only the hCG-stimulated 
but not the basal steroidogenic rate was inhibited by NO donors (including SNAP). 
Furthermore, the present data suggest that the endogenous production o fNO by TM3 
cells could be very low or non-existing, and thus even in the presence of NOS 
inhibitor, the VEGF gene expression could not be increased by removing the 
inhibition from endogenously produced NO. However, it should be cautioned 
whether such findings in a cell line could be extrapolated to the in vivo situation of the 
whole testis. Several studies have demonstrated that the testis is capable of 
endogenously producing NO either under the basal state through the constitutively 
expressed NOS - eNOS and nNOS [Zini et al, 1996; Davidoffe/ al, 1997; Lissbrant 
et al, 1997] or under the activated state by the inducible NOS - iNOS [Stephan et 
al, 1995; Tatsumi et al, 1997]. The local NO production was also shown to be 
important in the regulation of androgen production from the Leydig cells [Adams et 
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al, 1996; Del Punta et al, 1996; Bauche et al, 1998]. Thus there is little doubt that 
‘ in vivo Leydig cell activity is under the regulation of locally produced NO, and this 
may include the control ofVEGF expression. 
4.4 Effect of cadmium on VEGF mRNA levels in TM3 and TM4 cells, and in 
adult rat testes -
The present study demonstrated that in testicular cell lines and in the testis, 
cadmium treatment induced an upregulation of VEGF expression in vitro and in vivo, 
respectively. I t is likely that the increase in the testicular levels of VEGF mRNA 
reflects the changes occurring in Leydig cells and Sertoli cells, since cell lines derived 
from these two cell types responded in vitro to Cd^^ with a similar time-course as in 
vivo to give a significant induction ofVEGF expression at 6-12 hours after treatment. 
Furthermore the in vitro and in vivo induction of VEGF expression by cadmium were 
both inhibited by dexamethasone treatment. 
It is known that transition metal ions such as Co】+，Ni〗+ and Mn〗+ can mimick 
the effect of hypoxia to upregulate VEGF gene expression [Ladoux & Frelin，1994]. 
In the study of myocyte-enriched cultures prepared from new born rats [Eyssen-
Hemandez et al, 1996], Cd】+ was shown to be capable of inducing an increased 
expression ofVEGF. With 10 ^ M CdCl2, there was a 4-fold stimulation of the VEGF 
expression in myocytes. Thus Cd〗+ concentration found to be effective on VEGF 
expression in myocytes could similarly produce an effect in TM3 Leydig cells and 
TM4 Sertoli cells (10-30 J^V1). Since in this previous study, the effects of Cd〗+ and 
Cc)2+ were examined together with anoxia, the conclusion was that they worked 
through similar mechanism, possibly by activating the oxygen sensing mechanisms 
responsible for mediating the anoxic or hypoxic induction of VEGF. Nevertheless, it 
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cannot be entirely ruled out that other mechanism unique to cadmium is also operating 
in the testis and giving rise to its higher sensitivity to cadmium-induced vascular 
permeability increase. 
The upregulation of VEGF expression in testicular cells and in the testis 
appears to have provided a possible explanation for the cadmium-induced 
permeability increase in the testicular vasculature. On an equimolar basis, VEGF is 
about 5000 to 50,000 times more potent than histamine in inducing vascular 
permeability increase [Dvorak et al, 1995]. The present observation that inhibition of 
- Cd-induced increase in VEGF mRNA levels also abolished the vascular permeability 
increase and the associated haemorrhagic changes in the testis, appears to have 
provided strong evidence linking the vascular permeability increase induced by 
cadmium to the action ofVEGF. 
It has been proposed that the cadmium-induced vascular permeability changes 
in the testis does not rely on factors originating from Leydig cells since the selective 
destruction of these cells by ethane dimethane sulfonate OEDS) treatment did not 
abolish the vascular changes [Bergh, 1990]. The data presented here appeared to 
provide an alternative explanation to the findings. In the testis, both Leydig cells and 
Sertoli cells are capable of synthesizing VEGF and responding to Cd〗+ with increased 
VEGF gene expression, thus the Leydig cell is still involved in the Cd-induced 
permeability changes in the testis but its role could be taken over by the Sertoli cell 
following its selective removal by EDS. 
The present study demonstrated that Cd-induced increase in VEGF expression 
in TM3 cells and in the whole testes could be inhibited by dexamethasone treatment. 
Dexamethasone is a known negative regulator ofVEGF expression and it antagonizes 
the VEGF-induced vascular permeability increase especially the ones caused by 
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VEGF-derived from tumours that produce vasogenic edema [Bruce et aL, 1987; 
Criscuolo & Balledux，1996]. Similarly in the testis, dexamethasone was able to 
prevent the Cd-induced vascular permeability increase. In adult rats, a 3-day pre-
treatment with 4 injections of 1 mg/kg body weight dexamethasone resulted in the 
complete loss of the haemorrhagic appearance in the testis, that was normally seen at 
6 hours after the injection of 6 mg!kg bw CdCl2. The inhibitory efFect of 
dexamethasone on Cd-induced increase in VEGF mRNA levels in TM3 cells is in line 
with other reports of its in vitro effects on various other cell types under a state of 
- stimulated VEGF expression [osteoblasts: Harada et al, 1994; ovine pulmonary 
smooth muscle cells: Kkkamp et al, 1997; human vascular smooth muscle cells: 
Nauck et al, 1998]. Nevertheless, it should be pointed out that in some cells, the 
basal VEGF expression is also inhibited by dexamethasone [pituitary folliculostellate 
cells: Gloddek et al” 1999; rat glioma cells: MacHein et al, 1999; human meningioma 
cells: Tsai et al, 1999] but it does not appear to be the case for TM3 cells. 
The evidence so far supports that inhibitory efFect of dexamethasone on 
VEGF expression is mediated through a glucocorticoid receptor (GR)-dependent 
[Weissman et al, 1987; Heiss et al, 1996; Gloddek et al, 1999] as it can be inhibited 
by the use of specific GR antagonists - mifepristone (RU486). It has not been 
determined in the present study whether dexamethasone efFect on VEGF mRNA 
expression in TM3 Leydig cell is dependent on interaction with the GR. However, 
both Leydig cells [Schultz et al, 1993] and Sertoli cells [Levy et al, 1989b] have 
been shown to possess the GR. 
In this study, it was noted the VEGF response in TM3 and TM4 cells to CcP+ 
could not be maintained with time. Part of this could be related to a direct toxic effect 
of cadmium on these cells. This was especially true for TM4 cells which gave a 
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smaller increase in VEGF expression with a quicker fall-out. When TM4 cells are 
tested at the highest concentration of CdCb being used (100 ^iM), there was a marked 
drop in VEGF mRNA levels to below basal which could be related to the death of 
TM4 cells. 
4.5 Effects of hCG, forskolin and phorbol ester on VEGF expression in TM3 
and TM4 cells 
Previous studies indicated that hCG induced endothelial cell proliferation and 
- vascular permeability increase in the testis following a single injection, and it was 
hypothesized that these changes were mediated through the action of VEGF. 
However, in the present study at the time scale when the in vivo effects could be 
observed (16-24 hours post-hCG), VEGF mRNA levels could not be upregulated by 
hCG treatment both in vivo in the rat testes or in vitro using TM3 Leydig cell line. 
The only significant effect that was observed with the effect of hCG was on MLTC-1 
cells which clearly showed a maximum increase in VEGF mRNA expression even at a 
very low dose of hCG (0.01 KJ/ml). It remains to be determined whether in the rats 
and in the TM3 cells, their non-responsiveness to hCG in terms of VEGF mRNA 
expression is also related to no changes in peptide secretion. It is possible that hCG 
may regulate the post-transcriptional step to increase the peptide concentration and 
hence biological activities. 
In order to study the differences in the response between the TM3 and 
MLTC-1 cells, the effect of forskolin [and an analog of cAMP - 8-(4-
chlorophenylthio)-cAMP sodium] were examined for its effect on TM3 (and TM4) 
cells. The results showed that the cAMP/protein kinase A pathway which would 
otherwise be responsible for mediating the effects of the respective actions o f L H and 
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FSH on Leydig cells and Sertoli cells were in fact intact in these cells. Thus the lack 
t 
ofresponsiveness to the hormonal stimulation could be due to the loss of the L H (and 
FSH) receptors from these cell lines as it has been pointed out in the information 
provided by the supplier - American Type Culture Collection. This notion was 
supported by the presence of VEGF response in MLTC-1 Leydig cells which retain 
their hormonal responsiveness to LH. 
Thus similar to what was reported for other cell types, VEGF expression in 
Leydig cells and Sertoli cells is likely to be regulated by ligands that operate through 
- cAMP/protein kinase A pathway. The cell types that were reported to show an 
upregulation of VEGF expression through the cAMP pathway include bovine 
granulosa cells [Garrido et al” 1993], rat thyroid follicular cells [Sato et al.，1995], 
human pheochromocytoma cell line ^PC12) [Claffey et al, 1992], rat cardiac 
myocytes pLevy et al, 1995], and rat osteoblasts pHarada et aL, 1994；. 
c-AMP responses are reported to be mediated via the transcription factors 
API and AP2 [Treisman, 1986; Angel et al, 1987; Imagawa et al., 1987]. The 
promoter region of the rat VEGF gene has been found to contain consensus 
sequences similar to the binding sites for API and AP2 [Garrido et al, l993'. 
Therefore, activation of these transcription factors may be critical in the induction of 
VEGF through the cAMP/protein kinase A pathway. 
Besides protein kinase A, protein kinase C was also shown to be important in 
mediating the control of VEGF expression in a variety of cell types. In the present 
study, PMA - an activator of protein kinase C, was shown to be a more potent 
stimulator of VEGF mRNA expression than forskolin in both TM3 and TM4 cells. 
On an equimolar basis, the PMA effect is more potent than forskolin and the 
117 
upregulation of VEGF mRNA levels could maintain for longer, lasting for at least 3 
hours. 
Previous studies indicated that PMA could stimulate VEGF expression in 
several model systems [Tischer et al, 1991; ClafFey et al., 1992] including rat cardiac 
myocytes [Levy et al, 1995], pericytes [Kim et al, 1998], vascular smooth muscle 
cells [Tischer et al, 1991; Williams, 1995], keratinocytes, mesangial cells [Tischer et 
al, 1991; Frank et aL, 1995; Iijima et al, 1993] and 3T3 fibroblasts [Finkenzeller et 
cd., 1992]. 
- PKC is not a single molecular entity, but consists of a family of closely related 
isoenzymes that differ in their structure, cofactor requirement, and substrate 
specificity [Williams, 1992]. Isoenzymes ofPKC [Kikkawa et al, 1989; Ohno et al, 
1991] are thought to play an essential role in the pathway for several factors that are 
able to activate VEGF. These factors include hormones and growth factors such as 
EL-6，basic fibroblast growth factor, and platelet-activating factor but also stressful 
conditions such as hypoxia [Ijichi et al, 1995; Ahmed et al，1998; Hata et al, 1999]. 
A possible mechanism of VEGF transcription induction is also suggested by the 
presence of a responsive element in the VEGF gene promoter. 
PMA induction of VEGF mRNA may act at the transcriptional level, or 
through by increasing the stability of VEGF mRNA. It has been described that for 
other genes, such as lactate dehydrogenase, c-fos, intercellular adhesion molecule-1, 
or ribonucleotide reductase, an increase in their mRNA half-life was observed after 
PMA treatment [Ohh et al, 1994; Huang et al, 1995; Gonzalez-Espinosa & Garcia-
Sainz, 1996]. This may explain why the PMA effect in stimulating an increase in 
VEGF mRNA levels in TM3 and TM4 cells is more lasting. 
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In summary, the present data indicate that both protein kinase A and protein 
kinase C pathways are likely to be involved in the regulation of VEGF expression in 
both Leydig cells and Sertoli cells. 
4.6 Effect of cytokines and growth factors on VEGF expression in TM3 cells 
The present study demonstrated among the cytokines and growth factors that “ 
were being tested, TNF-a, TNF-p, bFGF and TGF-pl (but not EL-la，EL-lp and JL-
6) were the ones which might have the effects ofincreasing VEGF expression in TM3 
- cells. 
I L - l a and EL-ip could come from a number of cellular sources in the testis 
including the testicular macrophages, germ cells and Sertoli cells [Bergh & Soder， 
1990; Gerard et al.，1991; Nehar et al, 1998]. However, neither of them were shown 
to have any effects on VEGF expression in TM3 cells. Whereas in the past, a number 
of studies showed that they had an effect on Leydig cell steroidogenesis [Lin et al, 
1991; Moore & Moger, 1991]. The reason for such a lack ofVEGF response in TM3 
cells to JL is unclear especially since EL-la and I L - i p have both been shown to 
upregulate VEGF expression in cultured synovial fibroblasts [Ben-Av et al, 1995] 
and aortic smooth muscle cells pLi et al, 1995], respectively. The effect ofEL-ip was 
also found to be both time and dose-dependent. As little as 0.1 ng/ml EL-ip was able 
to increase the VEGF mRNA level in vascular smooth muscle cells by 2-fold. 
In the testis, H^6 has been shown to be produced by the Sertoli cells [Stephan 
et al, 1997] and testicular macrophages [Afane et aL, 1998]. Previously, it has been 
demonstrated that the in vivo expression of TL-6 accompanies vascularization in the 
reproductive tissues [Motro et al, 1990]. EL-6 expression has been noted during 
wound healing and tumour growth pffirano et al, 1990; Mateo et al, 1994]. It was 
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suggested that EL-6 may induce angiogenesis and may also induce motility of cells 
• such as endothelial cells jKrano et al, 1990; Motro et al, 1990; Barker et al, 1991]. 
In C6 rat glioma cells and A431 human epidermoid carcinoma cells VEGF expression 
. i s induced by BL-6 [Cohen et al” 1996]. However, in the present study, no detectable 
effect of EL-6 on VEGF expression in TM3 cells could be observed. The reason for 
such a lack of response is not clear. It is possible that similar to the loss of 
responsiveness to hCGyUI, TM3 cells failed to maintain the full characteristics of 
normal cells. Alternatively, there is the recent suggestion that activin, which in the 
testis is being produced by Leydig cells [Lee et al, 1989], could antagonize the JL-6 
action in mediating some of the immune reaction. 
In this study, TNF-a and TNF-P produced a small and variable response in 
stimulating VEGF expression in TM3 cells. TNP-a and TNF-P may have originated 
from testicular macrophages [Calkins et al, 1990; Hutson, 1993] and germ cells [De 
et al, 1993] within the testis, and in the past, their effects are mainly associated with 
Leydig cell steroidogenesis [Moore & Hutson, 1994; L i et al, 1995] and Sertoli cell 
function pMauduit et al, 1993]. 
In general TNF has been known as a macrophage/monocyte-derived 
pluripotent mediator that can function as an angiogenic factor in one system and as an 
antiangiogenic factor in another system [Frater-Schroder et al, 1987; Leibovich et 
aL, 1987; Schweigerer et al., 1987; Sato et al, 1987]. Fajardo and co-workers 
[1992] demonstrate that this difference may be due to TNF concentrations - a low 
dose of TNF induces angiogenesis while a high dose inhibits it. Moreover, time of 
exposure is another controlling parameter [Mawatari et al, 1989; Mawatari et al, 
1991; Kohno et al, 1993; Shono et al, 1996]. Thus the small and slightly variable 
responses that were reported here with TNF-a and TNF-P effect on VEGF 
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expression in TM3 cells could be related to their concentrations used and the duration 
of action. Nevertheless, it should be noted that in previous studies, TNF-a has only 
been shown to potently inhibit VEGF-induced endothelial cell proliferation possibly 
by downregulation the VEGF receptor expression [Patterson et al, 1996]. Thus TNF 
action on VEGF action or expression remains not clearly defined and would require 
more studies. 
The results obtained in this study indicated that other direct or indirect 
angiogenic growth factors like bFGF and TGF-p, produced a time- and 
- concentration-dependent increase in VEGF mRNA levels in Leydig cells. In the 
testis, these growth factors may originate from Leydig cells, Sertoli cells and 
peritubular cells [Teerds et al, 1990; Mullaney & Skinner, 1993; Gautier et al, 
1994]. The present findings raise the possibility that in addition to their own effects 
on the angiogenic processes, bFGF and TGF-P1 may induce VEGF expression to 
potentiate in stimulating angiogenesis [Pepper et aL, 1992]. In the past, numerous 
studies have demonstrated that bFGF [Stavri et al” 1995; Tsai et al, 1995] and TGF-
P1 [Goldman et aL, 1993; Pertovaara et a/., 1994; Frank et al, 1995; Koochekpour 
et aL，1996] are potent stimulator of VEGF expression in a variety of cell types 
including vascular smooth muscle cells, fibroblasts, keratinocytes, epithelial cells, 
glioblastoma cells and glioma cells, 
Our studies confirm and extend previous reports that angiogenic growth factor 
and pro-inflammatory cytokines upregulate VEGF mRNA gene expression. Many of 
these cytokines and growth factors occupy a role in biological processes such as 
inflammation, wound healing, and tumour progression, in which angiogenesis takes 
part. Cytokines or growth factors can affect angiogenesis by influencing VEGF 
expression and/or induce release of VEGF protein. In the testis, such regulatory 
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pathways of Leydig cell (and Sertoli cell) VEGF expression would present another 
‘ example of paracrine/autocrine interaction, especially within the Leydig cells and/or 
between the Leydig cells and testicular macrophages. 
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